City Research Online

City, University of London Institutional Repository

Cross-talk between biometal ions and immune cells for bone repair

Shubo Liu [a,c], Zhengjie Lin [b], Wei Qiao [d,***], Bin Chen [a,**], Jie Shen [c,*]

[a] *Division of Orthopaedics and Traumatology, Department of Orthopaedics, Nanfang Hospital, Southern Medical University, Guangzhou, PR China*
[b] *3D Printing Clinical Translational and Regenerative Medicine Center, Department of Stomatology, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, PR China*
[c] *Shenzhen Key Laboratory of Spine Surgery, Department of Spine Surgery, Peking University Shenzhen Hospital, Shenzhen, PR China*
[d] *Applied Oral Sciences and Community Dental Care, Faculty of Dentistry, The University of Hong Kong, Hong Kong S.A.R., PR China*

ARTICLE INFO

ABSTRACT

Biometal ions are crucial in the structure and function of living organisms and have extensively been employed to promote bone tissue regeneration. Nevertheless, the biological functions of biometal ions and the underlying mechanisms responsible for their pro-regenerative effects remain incompletely understood, since bone repair is an intricate physiological process involving multiple cell types and signals. Recent accomplishments in the osteoimmunological field have revealed the momentous involvement of the immune system in mediating the therapeutic effects of biometal ions. The inflammatory factors secreted by immune cells contribute to bone cell migration, activation, and proliferation. This review summarizes the immune system and its constituent cells, followed by the current perspective on immunomodulation during bone healing. Next, the physicochemical and physiological properties of various biometal ions, including lithium, sodium, potassium, magnesium, calcium, strontium, vanadium, iron, cobalt, copper, and zinc, are thoroughly reviewed. In addition, the interactions between biometal ions, immune cells, and bone tissue are discussed, aiming to provide insights into the prospective development of novel approaches to bone tissue regeneration by harnessing the therapeutic potential of these biometal ions.

1. Introduction

Bone injuries and defects have long been primary reasons for global mortality and disability [1]. There were 178 million new fractures worldwide in 2019, with an increase of 33.4% since 1990 [2]. In China, bone injuries are ranked as the fifth cause of mortality, surpassing the prevalence of various other diseases [3]. Between 1990 and 2019, the number for incidence of fracture in China increased from 12.54 million to 21.27 million, while the number for prevalence of fracture significantly raised from 28.35 million to 67.85 million [4]. Managing and reconstructing bone injuries, including sizable bone defects, delayed unions, and non-unions, pose persistent challenges in medicine [5,6]. Therefore, therapeutic strategies and mechanisms have been developed for the bone healing process. Natural and synthetic osteogenic materials have demonstrated their ability in cellular adhesion, migration, proliferation, and differentiation, thereby facilitating osteogenesis. These materials offer the necessary support for cellular processes, aiding bone regeneration and restoration [7–9]. Bioactive molecules, such as hormones [10], cytokines [11], and growth factors [12], function

in the bone healing and regeneration process. These molecules activate intricate signaling cascades within cells, effectively regulating cellular behaviors and promoting osteogenic differentiation and proliferation. Biomechanical factors adjust the mechanical stimulation of bones and enhance local stability to accelerate bone growth [13]. However, the limitations of established therapeutic strategies are amplified following implementation. These include insufficient donor supply or poor bioactivity of the required materials, high cost, short bioactive half-life of bioactive factors, and the low operability of mechanical stimulations [14]. Considering this, researchers are still exploring new strategies to repair bone injuries.

In recent years, osteogenesis regulated by the immune system has been affirmed as a powerful therapeutic strategy because immune cells are crucial for cell function and, in turn, for homeostasis and recovery from injury [15,16]. Bone tissue functioning not only as a structural component of the musculoskeletal system but also as an integral part of the immune system [17]. Immune cells and local bone cells are synthesized into the traditional osteogenic environment to form an "osteoimmune system" [18]. The association between the immune system and os-

Fig. 1. Schematic illustration of properties and functions of biometal ions. Source: Created with BioRender.com.

seous homeostasis has garnered significant attention due to their strong regulatory relationship. Extensive research has confirmed the crucial role of crosstalk between immune cells and bone cells within bone regeneration. This interaction is essential for sustaining the balance between osteogenesis and osteolysis, ultimately contributing to the overall health and integrity of the skeletal system [19,20].

Metallic elements are vital for cellular structure, catalysis, and signaling [21]. These are indispensable cofactors of enzymes, either prosthetic groups or coenzymes, and are responsible for the direct or analogous activation of ion channels and secondary signaling pathways [22,23]. In recent decades, metal ions have gained considerable research attention as regenerative improvers for bone tissue repair, and the release of metal ions has been found to promote implant–bone integration and regeneration [24]. The distinctive characteristics of metal ions have given rise to novel strategies to augment immunomodulation and tissue healing. Immune cells can interact with biometal ions at biologically safe concentrations locally within tissue microenvironments systemically [25]. Immune cells exhibit sensitivity to ions, and their mechanisms and behaviors can be modulated, to some degree, by these inorganic species. The interactions among bone cells, inflammatory mediators, and components of the immune system involved in bone regeneration remain a topic of significant scientific interest for clinicians and researchers [26,27]. However, the intricate mechanisms underlying the

interactions between multiple systems necessitate further exploration. The elucidation of the complex interrelationship of the immune system and the skeletal system in the context of biomaterial implantation is an evolving frontier of scientific inquiry, still in its incipient stages. Consequently, an urgent need is to explore further and understand the interactions between biometal ions and multiple systems (Fig. 1).

2. Immune system and immune cells

2.1. Immune system

The immune system in humans is composed of innate and adaptive immunity, each with unique characteristics. These systems vary regarding the rapidity and specificity of the immunological response, immune cells, cytokines, and biological macromolecules involved, and the duration and intensity of the inflammatory response [28,29]. Despite these differences, these two immune responses interact throughout the immune regulatory process to maintain our body's homeostasis. Innate immunity serves as the foundation of adaptive immunity through the presentation of antigens, while the immune substances produced by adaptive immunity also shape the actions of innate immunity. For instance, macrophages can present antigens to lymphocytes, activating them to

eliminate target cells. Concurrently, antibodies and cytokines also modulate macrophage chemotaxis, activation, and phagocytosis [30].

Innate immunity serves as a tissue barrier mechanism involving immune cells (monocytes, macrophages, neutrophils) and biomacromolecules (complement, cytokines, inflammation-associated proteins). These constituents are pivotal in orchestrating innate immunity, thereby turning into the cornerstone of the acute immune response. Innate immunity is distinguished by its broad-spectrum efficacy, rapidity of action, and inherent stability, rendering it the organisms' fundamental and indispensable immune defense system [31]. Adaptive immunity, also called specific immunity, is triggered by specific antigenic substances during infection or active vaccination, resulting in a robust, targeted immune response and potent killing effect against the respective pathogen. It is thus more accurate than innate immunity but takes a longer time to develop. Adaptive immunity can be further divided into cellular and humoral immunity, involving T and B lymphocytes, respectively. Cellular immunity is facilitated primarily by cytotoxic T lymphocytes, which account for eliminating infected cells and intracellular pathogens. In contrast, humoral immunity is primarily driven by plasma cells that synthesize and secrete immunoglobulins (Ig) upon antigen stimulation, binding to target antigens and participating in immune responses [32].

2.2. Immune cells

2.2.1. Monocytes/macrophages

Monocytes and macrophages possess a diameter of 15 to 22 μm and a pin-like nucleus originating from the mononuclear phagocytic system [33]. Monocytes can be distinguished by identifiable surface markers, which shape a uniform size and distinctive nucleus. Typically, they are usually classified into three subtypes based on the intensity of fluorescence of cluster of differentiation (CD) 14 and CD16 on their surfaces: the classical monocyte with $CD14^{++}/CD16^{-}$(CD14 overexpressed and CD16 not expressed), the non-classical monocyte with $CD14^{dim}/CD16^{++}$(CD14 weak expressed and CD16 overexpressed), and the intermediate monocyte with $CD14^{++}/CD16^{+}$(CD14 overexpressed and CD16 moderate expressed) [34].

Monocytes are the common precursors of macrophages. Upon receiving signals from infected sites, monocytes are among the first to arrive at the inflammatory tissues from the bloodstream, where they proliferate and differentiate into macrophages to bolster the innate response [35]. Monocytes themselves also perform phagocytosis, either with the assistance of antibodies or immune complexes or by recognizing pathogens through pattern-recognition receptors (PRRs) [36]. PRRs can recognize pathogen-associated molecular patterns (PAMPs), which are related to infected pathogens, or damage-associated molecular patterns (DAMPs), which are related to fragments of dead cells and non-infectious debris [37].

Macrophages, derived from monocytes or residing in tissues, represent a specialized subset of white blood cells that serve a pivotal role in defending against foreign invasions. They are ubiquitously present throughout the body but classified into distinctive forms with different names based on their residing sites and surface markers. For instance, macrophages residing in the liver are specifically referred to as Kupffer cells, those present in the nervous system are known as microglia, and in bone tissue, they are commonly referred to as osteal macrophages (OsteoMacs) [38]. Macrophages are so named because of their large size and remarkable phagocytic capacity. In the initial phase of innate immunity, macrophages recognize foreign molecules and exert profound effects–presenting antigens, performing phagocytosis for self-digestion, and releasing a series of pro-inflammatory or anti-inflammatory cytokines. These activities upregulate the inflammatory responses and intricately result in the harmonious coordination of the entire immune system [39]. Macrophages exhibit crucial functions encompassing the recognition, phagocytosis, and elimination of bacteria and other detrimental pathogens. The detection of microbes is accomplished by PRRs expressed on the macrophage surface [40].

For phagocytosis, a central function of the macrophages, pathogens are engulfed into a phagosome, which then fuses with a lysosome and digests pathogens by enzymes and toxic peroxides [41–43]. Additionally, macrophages orchestrate the release of a spectrum of chemokines and cytokines, which serve as mediators in eliciting inflammatory and antibacterial actions. Notably, immunological inducers including nitric oxide synthase (NOS) and interleukin-1 (IL-1) facilitate the activation and selective homing of supplementary immune cells to the inflammatory site [28].

Typically, the subtypes of macrophages can be classified into M1 (pro-inflammatory) and M2 (anti-inflammatory) types based on their cytokine productions. M1 macrophages primarily contribute to inflammation by promoting phagocytic responses and releasing cytokines [44]. M1 macrophages induce NO production by iNOS, which may exacerbate the inflammatory response under specific conditions. This inflammatory response can provide a suitable environment for macrophages to phagocytose pathogens. However, it may also have a killing effect on normal tissues [45]. By contrast, M2 macrophages predominantly release anti-inflammatory cytokines: IL-4, IL-10, IL-13, and transforming growth factor (TGF), to facilitate tissue regeneration at the injury site. In the present study, M2 macrophages can be further divided into four subtypes: M2a, M2b, M2c, and M2d, each of which exhibits nuanced variations in their functional attributes [46,47]. IL-4 and IL-13 induce M2a macrophage differentiation, which is well-known as classically activated alternatively activated macrophages. These M2a macrophages function in the tissue regeneration process by producing various components of the extracellular matrix [37]; M2b macrophages are commonly recognized as regulatory macrophages (Mregs), characterized by their secretion of high levels of IL-10 and lower doses of IL-12 than other M2 cell subtypes [48]; M2c macrophages can be selectively induced in response to glucocorticoids and TGF-β, leading to the acquisition of a distinct phenotype. M2c macrophages exhibit an enhanced capacity for secreting elevated levels of TGF-β and IL-10, contributing to their immunoregulatory and tissue-reparative functions [49]; M2d macrophages display a pro-angiogenic role by releasing vascular endothelial growth factor (VEGF), TGF-β, and IL-10 [50]. Nevertheless, it is crucial to acknowledge that recent studies have revealed a more complex spectrum of macrophage phenotypes that extends beyond the traditional M1 and M2 classifications. Moreover, macrophages have been found to possess the ability to transition between phenotypes [44].

There are two main sources of macrophages: residential cells and blood infiltration [51]. Both sources are essential for regulating and stabilizing the injured site. Before infection or inflammation, resident macrophages are defensive patrols that proliferate regularly in the tissue and are more likely to transform into M2 phenotypes. Upon sensing a local infection or foreign substance, resident macrophages undergo activation and secrete a variety of inflammatory cytokines and chemokines: IL-1, IL-6, IL-8, IL-12, and tumor necrosis factor-α (TNF-α). These molecules serve to attract other immune cells to the affected site against the aberrant stimulus [52]. IL-8 which is secreted by local macrophages recruits neutrophils from blood vessels [53]. With the help of IL-12, NK cells are drawn into the signal site and release cytokines to maintain macrophage activity [54]. At the early stage of inflammation, macrophages present at strategic locations remove dying cells and engulf foreign particles. If needed, resident macrophages can recruit circulating monocytes to diseased sites, where they differentiate into activated macrophages later [55]. Monocytes, recruited by cytokine chemotaxis and differentiated by the local inflammatory cues, provide a larger proportion of activated macrophages responsible for the regulation of the immunological microenvironment.

2.2.2. Dendritic cells

Dendritic cells (DCs) are widely acknowledged as the most proficient antigen-presenting cells (APCs) within the adaptive immune system [35,56]. They perform the tasks of engulfing, digesting, and presenting antigens to immature T cells as a transporter and activator. Be-

fore penetrating tissue barriers and entering the bloodstream, pathogens like bacteria and viruses are recognized by numerous toll-like receptors (TLRs) expressed on the local DCs. They are internalized by DCs and subsequently processed into smaller particles that are compatible with major histocompatibility complex (MHC) class I and II molecules. The presence of adhesion and co-stimulatory molecules empowers DCs to carry out antigen presentation [57]. Accompanied by alterations in cell surface morphology, structure, and molecular signaling, dendritic cells undergo migration from the site of infection to the secondary lymphoid organs. Among these, DCs present antigens to primary lymphoid cells, thereby triggering their activation and initiating the process of adaptive immunity [57]. Subsequently, DCs become activated, limiting their ability to process new antigens and instead concentrating on presenting antigens to naive T lymphocytes [57]. They congregate in the lymph node, but only a select few are carefully chosen by MHC-peptide complexes to evolve into effector T cells, given their potency when targeting cells [58].

2.2.3. Granulocytes and mast cells

Granulocytes are categorized as neutrophils, eosinophils, basophils, or mast cells based on their chemical properties. Their cytoplasm houses granules that are released and act on infected sites [59]. Neutrophils carry out functions identical to macrophages in engulfing microorganisms; however, they have a shorter lifespan and circulate independently until they are summoned to an inflammatory response [60]. Neutrophils are ubiquitous in the blood and bone marrow cavity in response to the initial infection. During the early stages of an infection, neutrophils exhibit important functions by undergoing degranulation and engaging in phagocytosis at the sites of infection. These processes are crucial for eliminating pathogens and foreign substances. However, it is worth noting that these activities can also exacerbate inflammation and contribute to the formation of pus, which is also a consequence of the immune response [61].

In the connective tissue, mast cells, basophils, and eosinophils function as inductors of acute hypersensitivity [62]. High-affinity immunoglobulin E receptor I (FcεRI), which is produced on their surfaces, may bind IgE released by plasma cells and generate an irreversible binding force [63]. These cells are, therefore, primed to identify pathogens and bind to their antigen isotypes. Upon binding with IgE antibodies through interactions with two or more FcεRI molecules on their surface, pathogens trigger rapid activation of mast cells or basophils. Eosinophils employ their FcεRII receptors and pre-packaged granules to inflict damage upon parasites [64]. Basophils, distinguished by their two-lobed nucleus and numerous cytoplasmic granules, represent one of the least abundant cell types found in both the bone marrow cavity and the bloodstream. Upon infection, mature basophils are released from the bone marrow with a secretion of histamine and prostaglandins, which induce capillary dilation and increased permeability. Consequently, blood flow is enhanced, creating an inflammatory milieu at the injury site. This process facilitates the migration of phagocytes, contributing to the immune response against pathogens [65].

2.2.4. Nature killer (NK) cells

Natural killer cells (NK cells) constitute 5 to 25 percent of total lymphocytes in a healthy individual [66]. The major assignment of NK cells is to eradicate infected or harmful cells. NK cells can be activated and recruited through the action of cytokines released by infected cells. These secreted factors further stimulate phagocytosis and macrophage lysis to promote direct cell killing [67]. During the antibody-dependent cell-mediated cytotoxicity (ADCC) process, antigens are recognized by FcγRIII (CD16) receptors binding to antibodies and then leading to NK cell activation. This activation triggers the production of cytolytic granules, ultimately resulting in the apoptosis of the targeted cells [68]. The fluorescence intensity of specific markers, such as CD56, can be utilized to differentiate between different subtypes of NK cells. Classification of NK cells refers to CD56^{bright} or CD56^{dim} based on the intensity of CD56

fluorescence [69]. CD56^{bright} NK cells comprise the majority of NK cells with several cytokine productions (IL-2, IL-12, type I interferon), while CD56^{dim} NK cells are identified by their Characteristics of killing [70].

2.2.5. T lymphocytes

T lymphocytes assume a fundamental and indispensable function in orchestrating the adaptive immune response. Due to the presence of the T-cell receptor (TCR) on the cell membrane, they possess a unique characteristic that sets them apart from other lymphocytes. T cells experience a complex process of maturation within the thymus gland. Serving as formidable assassins against infected and tumor cells, these remarkable cells exhibit surface markers, primarily CD4 and CD8, which are indicative of their distinct identities. To attain full maturity and functionality within the adaptive immune response, early thymic progenitor (ETP) cells, initially lacking both CD4 and CD8 markers, undergo a series of intricate developmental stages, including TCR development, positive selection, and negative selection [71]. T cell maturation requires the combination of functional TCR. Once a functional TCR has been developed, the T cell will go through the positive selection with rearrangement of the TCRα locus. Then, positive selection enables progenitor cells to develop into adult cells [72]. T lymphocytes expressing TCRs that bind strongly to MHC class I molecules may be prompted to undergo further maturation and differentiation [73]. These double-positive (CD4$^+$/CD8$^+$) cells are then evaluated by MHC class I and II to determine which chemical they bind. CD4 interacts specifically with MHC class II, while CD8 binds to MHC class I. The contact between a particular receptor and a self-MHC complex, therefore, affects whether a T cell matures into a T cell possessed either CD4$^+$ or CD8$^+$. In contrast, negative selection identifies antigen receptors that bind too strongly with self-peptides and eliminates their numbers [74,75]. Consequently, these highly responsive lymphocytes receive apoptotic signals that prompt cell death. After the whole process, only 2% of lymphocytes become mature immunocompetent T cells with CD4$^+$ or CD8$^+$ and circulate in the bloodstream.

Subsequent to antigen recognition, a select population of naive T lymphocytes undergoes a process of intricate differentiation, culminating in the formation of memory T lymphocytes. These cells possess a remarkable capacity to rapidly expand into a formidable cohort of effector T cells upon subsequent encounters with their cognate antigen. After that, Memory T cells will further differentiate into effect Memory T cells (T$_{EM}$) or central memory T cells (T$_{CM}$) according to the intensity of antigen stimulation. In the peripheral blood, T$_{CM}$ cells predominantly exhibit the CD4 phenotype, while T$_{EM}$ cells primarily bear the CD8 marker [76]. Depending on the types of pathogens and the environment of infection, T cells have multiple differentiated states [77]. Furthermore, mature T lymphocytes can be subdivided into CD4$^+$ helper cells and CD8$^+$ killer cells. CD4$^+$ helper T cells support other immune cells in coordinating and enhancing immune activities, such as cytotoxic T cells and B cells. CD8$^+$ killer T cells possess a dual ability to directly eliminate virus-infected cells or tumor cells, while also releasing cytokines that augment the recruitment of other immune cells and enhance their cytotoxic capacity. Additionally, regulatory T cells (Treg) serve to suppress inappropriate immune responses, specifically from other T cells. They secrete cytokines that regulate abnormal immune functions, maintaining immune balance.

Helper T cells (Th) are subtypes of CD4$^+$T cells with supplemental and auxiliary instructions that are divided into Th1, Th2, Tfh, Th17, and Treg [73,78]. Effector Th1 cells take part in the immune response by regulating macrophages to enhance the efficiency of pathogen elimination during infections. The interaction between Th1 cells and macrophages yields several beneficial effects. It promotes the enhancement of phagocytic activity, enabling macrophages to digest engulfed pathogens more effectively. Moreover, Th1 cells stimulate macrophages to produce and release microbicidal agents, including oxygen radicals, nitric oxide (NO), and proteases. These potent substances exert antimicrobial effects, contributing to the extermination of invading pathogens

and bolstering the immune defense against infections [79]. Th1 cells express TLRs to identify antigens presented by MHC II molecules on macrophages and activate them preferentially [80]. Once they establish a strong connection with each other, signals are exchanged throughout the whole process. IFN-γ and CD40L released by the Th1 cells stimulate the activation of macrophages [79]. Within infected tissues, the release of molecules such as TNF-α and IL-2, influences the differentiation of macrophages into distinct functional subsets. Th2 cells exert inhibitory functions via secreting cytokines (TGF-β, IL-4, IL-10, IL-13) on macrophages [81]. They may also damage healthy cells by magnifying the signals of parasite infections, which will activate basophils and mast cells to generate an allergic reaction [82,83]. The maturation of Tfh cells leads to an enhanced antibody production of B cells [84]. By recognizing the antigen: MHC complex, Tfh cells bind to the particular antigen and subsequently release CD40L to combine with CD40 on the B cell's surface. Th17 cells stimulate neutrophils to respond to fungal and bacterial infections. However, the overactivation of Th17 cells may cause type IV hypersensitivity and several related diseases, including asthma and rheumatoid arthritis (RA) [85,86]. Treg cells can reduce the self-reaction of relatively high-functional CD4$^+$T cells by negative feedback [87]. Effector T cells become activated and exhibit their cytotoxic function upon encountering antigen-presenting cells. They effectively eliminate target cells that are infected or cancerous. By contrast, Treg cells employ immunomodulatory mechanisms to maintain immune balance. The inhibitory effect of Treg cells upon effector T cells prevents excessive damage to normal tissues in vivo, minimizing the potential for immune-mediated destruction. Treg cells are essential in maintaining immune tolerance and preventing autoimmune reactions [87]. Based on the study of T cell subtypes above, other subtypes of Th cells have been discovered, such as Th9 and Th22 cells. Th9 cells produce IL-9 to defend against helminths and cell-dependent allergic inflammation [88], while Th22 cells release IL-22 and participate in self-immune diseases like Crohn's Disease and RA [89].

CD8$^+$T cells are called cytotoxic T cells due to their cell-killing capability [90]. Upon recognition of MHC1 molecules by CD8$^+$T cells, cytotoxic mediators including perforin, serine esters, interferon, and tumor necrosis factor, are secreted to destroy target cells. After identifying particular antigen-presenting cells, CD8$^+$T cells attach to target cells and release lytic granules at the fusion site [91]. This process, also known as programmed cell death, prevents the production of inflammatory factors and transforms potential pathogens into a static form that can be engulfed. CD8$^+$ T cells secrete cytokines: Interferon gamma (IFN-γ), and IL-2, for upregulating macrophages' ability to clear apoptotic cells. This cooperation between CD8$^+$ T cells and macrophages maintains tissue homeostasis and alleviates inflammation by promoting the efficient removal of cellular debris [91].

2.2.6. B lymphocytes

B lymphocytes are a unique subtype of lymphocytes from the bone marrow. They are characterized by B-cell receptors (BCRs), which bind to antigens and initiate an antibody response. The dominating function of B cells is to produce a wide variety of antibodies, resulting in a targeted immune response [92]. This process requires antigen activation. In draining lymph nodes, B cells detect antigen-MHC II complexes provided by follicular dendritic cells or macrophages and activate CD40 ligand expression [93]. Then, antigen-activated B cells migrate from the B region to the juncture between B cells and T cells, where they form a cognate pair to exchange cytokines. This process enhances naive B cells to differentiate into plasma cells for generating antibodies or transforming into memory B cells for possible secondary infections in the future.

Plasma cells produce antibodies to neutralize infections and activate effector cells to eradicate pathogens [94,95]. The antibodies they secreted can be classified as IgM, IgA, IgE, IgG, and IgD. IgM is the first antibody isotype that plasma cells produce in the blood and tissues when encountering infections [96]. The pentameric form of IgM

binds to pathogens, traces complement receptors on phagocytes, and then activates the immune system through the classic pathway. However, IgM has the disadvantage of being too large to permeate tissues and having a limited affinity for combining with infections [97]. After the adaptive immune response, mature IgG with high affinity is created to cover pathogens, while monomeric IgA is transported to the particular receptors on phagocytes [98]. In addition, dimeric IgA is secreted in the mucosal tissues of the digestive, respiratory, and urogenital systems to serve as the initial line of immunological defense [99]. IgE acts as the primary source of acute allergy responses identified by mast cell Fc receptors [100]. Mast cells carry substantial amounts of IgE on their surface because of their high affinity after combination [101]. Cytokines regulate B cells in significant ways. IFN-γ, for instance, causes the B cell to create a powerful opsonizing IgG antibody; IL-4 causes it to make IgE; IL-5 increases the synthesis of IgA, and TGF-β triggers the release of IgG2b and IgA [102].

3. Immunoregulation during bone healing

Bone fractures are a pervasive medical issue within human populations, with an escalating incidence reported in recent years [103,104]. Typically, fracture healing can be categorized into two subtypes: direct (primary) and indirect (secondary) repair. Direct bone healing necessitates a minimal fracture end gap, typically less than 0.1 mm, facilitating direct ossification and subsequent Haversian remodeling without the need for callus formation [11]. Conversely, indirect or secondary fracture repair is a more prevalent mode of bone healing, typically associated with fractures that maintain some degree of mobility. This process involves the recruitment of mesenchymal stem cells (MSCs) and their differentiated progeny, including osteoblasts and osteoclasts, to the fracture site, where they contribute to matrix deposition [16]. Secondary fracture healing is traditionally delineated into four stages: the inflammatory phase, the cartilaginous callus phase, the bony callus phase, and the remodeling phase [105]. The healing process involves the restoration of bone continuity, regeneration of surrounding soft tissues, and, crucially, angiogenesis and neurogenesis [11]. Fig. 2 provides a comprehensive depiction of the origins and differentiation pathways of osteogenic and immune cells in the bone marrow cavity.

3.1. Inflammation stage

The inflammatory phase of bone healing is triggered when damage to surrounding vasculature initiates clotting and hematoma formation to arrest bleeding [106–108]. A group of inflammatory immune cells are subsequently recruited to commence the inflammatory response. Polymorphonuclear neutrophils (PMN), including neutrophils, infiltrate the hematoma in substantial numbers early on, secreting chemokines such as Chemokine ligand 2 (CCL-2) and IL-6 to draw long-lived macrophages into the fray during the ensuing phase [109]. Granulation tissue supplants the hematoma with the ingress of immune cells, predominantly neutrophils, and macrophages [110]. This inflammation phase serves to purge potentially cytotoxic debris and necrotic cells from the lesion site, transitioning the microenvironment towards an anti-inflammatory state [111,112]. Fig. 3 delineates the four stages of bone healing, highlighting the immune cells associated with each phase as well as the morphological changes occurring during bone healing.

Inflammatory cells actively participate in the resorption of injured tissues and contribute to the formation of new bone matrix [113–115]. Monocytes differentiate into macrophages, while resting macrophages transition into an activated state, inciting intense inflammation and presenting MHC-peptide complexes to dendritic cells, thus sparking the adaptive immune response [116,117]. Generally associated with allergic reactions, mast cell mediators, including histamine and VEGF, can expedite vascularization and augment the proliferation of MSCs and osteoblasts [118–121]. NK cells may also function in the early phase of inflammation, although the precise mechanisms remain elusive [122]. T

Fig. 2. The development of immune cells and bone cells. Source: Created with BioRender.com.

Fig. 3. Immune cells in different bone healing stages. Source: Created with BioRender.com.

and B cells launch adaptive immune responses once antigen-presenting cells have been activated. Generation of the T cell takes 3 to 28 days, whereas the generation of the B cell takes 3 to 5 days [123,124]. Unlike resident macrophages, which can potentially promote osteogenesis, circulating macrophages, typically classified as M1 type, are prone to stimulating inflammation and releasing inflammatory cytokines: IL-1, IL-6, macrophage colony-stimulating factor (M-CSF), TNF-α, to initiate the subsequent adaptive immune response [125,126]. Neutrophils attracted by IL-1 and TNF-α, contribute to the clearance of cellular and tissue debris. Under inflammatory conditions, neutrophils secrete a range

Fig. 4. Important ion channels and transporters on immune cells. Source: Created with BioRender.com.

of cytokines: IL-1, IL-6, IL-10, TNF-α, CCL2, CXC chemokine ligand 1α (CXCL-1α), and CCL4, to recruit monocytes and foster their differentiation into activated macrophages [85]. Upon the clearance of debris and pathogens, inflammation-induced cells and osteogenic cells collaborate to compose a cartilaginous callus. These cells secrete cytokines, including fibroblast growth factor (FGF), platelet derived growth factor (PDGF), and TGF-β, which foster the growth of granulation tissue and its transformation into a primary callus [18].

3.2. Cartilaginous callus formation

The cartilaginous callus formation stage serves as the initial phase in reestablishing bone continuity. Here, endothelial cells and fibroblasts create a sufficient blood supply within the granulation tissue, supporting nutrient metabolism. Concurrently, chondrocytes are drawn to the callus, stimulating chondrogenesis and endochondral ossification. This period sees an increased type II collagen expression and deposition of the cartilage matrix [127]. Meanwhile, the angiogenesis process is initiated with the production of a cluster of pro-angiogenic factors: VEGF, bone morphogenetic protein (BMPs), FGF-1, and TGF-β3 [128].

During this phase, macrophages continue to be present in the bone repair microenvironment. They play an immunomodulatory role and help remodel the cartilage callus. Working alongside neutrophils, they remove dead cells and debris left over from the inflammation stage [115]. While phagocytosis is a key function of macrophages, the cytokines they produce are also essential. These substances help regulate the metabolism of the fracture site's microenvironment and maintain bone homeostasis [129–131]. Inflammatory molecules: bacterial lipopolysaccharide (LPS), granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, stimulate the formation of

M1-type macrophages. By contrast, anti-inflammatory cytokines (IL-4, IL-13) promote the generation of M2-type macrophages. There's further polarization of regulatory and wound-healing M2 subtype macrophages to aid bone regeneration [111,132-135]. Lymphocytes also help to balance osteogenesis during the creation of the soft callus. T cells activate osteoclasts by producing receptor activator of nuclear factor-κB ligand (RANKL) for fibrin thrombus removal, while B cells secrete OPG, impacting the RANK/RANKL pathway by binding RANK receptors [123,136]. Despite B cells outnumbering T cells [136], various T cell phenotypes have significant roles during this phase. Helper T cells, in particular, crucially influence B cell development. IL-17, released by Th17 cells, has been demonstrated to induce osteoblast differentiation, simultaneously assisting in osteoblast maturation [137,138].

3.3. Bony callus formation

The process of bony callus formation, which follows the cartilaginous callus phase, begins with the infiltration of osteogenic cells. These cells prompt the cartilaginous callus to start endochondral ossification, leading to a more robust and rigid bony callus [105]. During this phase, chondrocytes transition into a hypertrophic state, expanding their size significantly by filling with collagen X. After another round of vascularization, hypertrophic chondrocytes release bone formation markers: alkaline phosphatase (ALP), osteopontin (OPN), osteocalcin (OCN), thereby stimulating the growth of the bony callus [139].

The fragile and pliable cartilaginous callus is resorbed by osteoclasts and immune cells [85]. As the inflammatory response subsides, the population of T and B lymphocytes declines. However, during the initial stage of callus formation, they reappear in the vicinity of the woven bone. The differentiation patterns of their subtypes undergo changes

compared to the inflammatory phase. The numbers of CD4$^+$ and CD8$^+$ T lymphocytes decrease while the proportion of Treg cells increases. Among B cells, the predominant population detected is naive B cells (B220$^+$IgM$^+$IgD$^+$). These lymphocytes reemerge in the callus and correlate with the inhibition of osteoclast formation in a time-dependent manner. This suggests that they may act on suppressing osteoclast activity and promoting osteogenic repair during the process of callus formation [123]. During callus formation, the differentiation of lymphocyte subtypes changes. Similar to the cartilaginous callus phase, M2 macrophages are the primary macrophage population observed during this stage, contributing significantly to tissue repair and regeneration [140]. In the subsequent phase, there is a transition from hyaline cartilage and woven bone to lamellar bone, which can be observed both histologically and mechanically. Similar to the cartilage callus formation phase, B lymphocytes infiltrate the luminal side of the callus. These B cells release RANKL and OPG to regulate the RANK/RANKL pathway [105].

3.4. Remodeling phase

During the remodeling phase, the initially formed woven bone hard callus transforms into a configuration of cortical and/or trabecular bone with a highly organized structure [105]. Osteoclasts originate from the monocyte-macrophage cell line with a function of decomposing bone tissue [141–143]. Simultaneously, osteogenic cells, particularly chondrocytes and osteoblasts, secrete matrix metalloproteinases (MMPs) to repair collagens and proteoglycans. The MMP superfamily, which includes matrix metalloproteinases 9 (MMP9) and MMP13, targets specific protein synthesis processes [144].

Immune cells that infiltrate during the remodeling phase also function within the osteogenic microenvironment. T and B lymphocytes primarily produce osteoclastogenesis inhibitory factor (OPG) and regulate the RANK/RANKL pathway leading to osteogenesis. Studies have illustrated that Th17 cells secrete IL-17, which can regulate the expression of RANKL, promote the generation and activation of osteoclasts, and aid in the reconstruction of new bone [52,145]. Meanwhile, macrophages that interact with osteoclasts promote remodeling and mineralization [140]. Mast cells reappear and enhance the resorption of the convex side of the callus [146,147].

4. Biometallic ions and immune cells

4.1. Alkali metals

The alkali metals constitute a group of elements that share striking similarities owing to the presence of a single outermost electron occupying an *s*-orbital, which readily undergoes ionization. This characteristic endows them with the lowest first ionization energies within their respective periods in the periodic table, primarily attributed to their low effective nuclear charges. The facile attainment of noble gas electronic configurations by relinquishing the outer electron further reinforces their unique behavior. However, the second outermost electron is situated within a filled electron shell, resulting in a significantly higher second ionization energy. Consequently, under typical conditions, alkali metals tend to form monovalent ions. Furthermore, as one progresses along the alkali metal series, an increasing trend is observed in both atomic radius and ionic radius, reflecting the larger spatial extent of the valence electron cloud.

In biological systems, alkali metal ions, notably sodium and potassium, are crucial for maintaining osmotic pressure and pH value. These ions interact with multiple ion channels and transporters on the cell membrane, thus necessitating meticulous regulation for basic homeostasis [148]. The atomic number of alkali metals influences their binding characteristics with biomacromolecules and their hydration preferences. Ion channels generally select one ion type based on its specific atomic radius. For instance, the leucine transporter (LeuT) transports leucine and

Na$^+$ across the cell membrane in the same direction. Within the atomic structure of LeuT, Na$^+$ is surrounded by six oxygen atoms originating from the main-chain carbonyl or side-chain hydroxyl atoms. These oxygen atoms carry only a partial negative charge, sufficient to neutralize Na$^+$ with an average Na$^+$-O distance of 2.28 Å for each oxygen atom [149]. Similarly, K$^+$ channels, like KcsA K$^+$ channel, form a selective structure based on the atomic radius of K$^+$. The KcsA K$^+$ channel comprises four K+ binding sites in a row, forming a selectivity filter. Due to its larger atomic radius, K$^+$ can attract eight oxygen atoms surrounding the ion with an average K$^+$-O distance of 2.84 Å [149]. However, Li$^+$ has not been comprehensively studied via specific proteins transporting into the cell.

4.1.1. Lithium

4.1.1.1. physicochemical and physiological properties of lithium. Lithium, a metallic element, is the lightest and possesses the smallest ionic radius among alkali metals, exhibiting the lowest reactivity [150]. Like other alkali metals, it readily forms a cation (Li$^+$) by losing a single valence electron. However, due to the proximity of the electron to the nucleus, the reactivity of lithium is lower. Lithium's small atomic diameter results in relatively high solubility in solution. The basic physical and chemical properties of lithium ion, including its ionic radius and oxidation state, are presented in Table 1, along with the other ions discussed later. As a monovalent ion, lithium can compete with other metal ions [151]. For example, the interaction between magnesium and lithium can be explained by the "diagonal principle," suggesting that lithium ions may compete with magnesium ions in biomacromolecule synthesis or simply reduce the intracellular concentration of magnesium ions [152]. Furthermore, Li$^+$ can traverse cell membranes via Na$^+$ or K$^+$ ion channels due to their similar chemical properties, resulting in a vital role in ion homeostasis. Despite the exact lithium transport mechanism remaining elusive, eight major transmembrane transportation mechanisms have been identified: (1) Voltage-gated Na$^+$ channels and Epithelial Na$^+$ Channels, (2) kidney sodium-phosphate cotransporter, (3) sodium-lithium countertransport, (4) sodium-proton pump, (5) ENA transporters, (6) NHA1 antiporter, (7) sodium-calcium/lithium exchange on the mitochondrial membrane, (8) pentameric ligand-gated ion channels (Fig. 5a) [153].

4.1.1.2. Immunoregulation of lithium. Beyond its anti-infection effects, studies have explored lithium's impact on immune cells (Fig. 5b). Lithium has been studied extensively in the field of immunology for its potential therapeutic applications in mood regulation, cancer treatment, infections, and autoimmunity. Li$^+$ ions, either by directly competing with magnesium or by inducing serine phosphorylation, can effectively inhibit the activity of glycogen synthase kinase-3 beta (GSK3β). It conducts as a negative indicator of the Wnt signaling pathway [154]. Depending on the inhibition of GSK3β by Li$^+$, the NF-κB pathway activates by Li$^+$ ions via a reduction of inflammatory cytokines: IL-1β, IFN-γ, IL-6, and monocyte chemoattractant protein (MCP1), and simultaneously an increase of anti-inflammatory cytokines: arginase 1 (Arg-1), IL-10, leading to M2 type macrophage polarization [155]. Although most research suggests lithium's anti-inflammatory actions alleviate inflammation-induced disorders, some studies have indicated the pro-inflammatory effects of lithium. Petersein et al. noted that lithium ions increased inflammatory cytokines production either alone or in combination with antidepressants [156]. LiCl treatment decreased the proportion of NK cells by over 43% after the sixth day but increased them by 2.5-fold in comparison with the control group with a prolonged 21-day treatment [157]. This result showed that the immunomodulatory impact of lithium ions was dependent on time and dosage. Liu et al. reported an elevation of inflammatory cytokines in immature DCs when exposed to LiCl, resulting in an increased activation of monocyte-derived dendritic cells [154]. T and B lymphocytes can be affected by lithium ions as well [155]. Lithium compounds have been demonstrated to enhance the synthesis of IgG and IgM in B cells, along with the enhance-

Table 1

Atomic properties of biometal ions.

Ion	Atomic number	Electron configuration	Electronegativity (Pauling scale)	Oxidation states*	Atomic radius (Calculated)	Ionic radius**	Ionization energy (kJ/mol)		
Lithium	3	[He] $2s^1$	0.98	+1	167 pm	+1: 90 pm	1st: 520.2	2nd: 7298.1	3rd: 11,815
Sodium	11	[Ne] $3s^1$	0.93	−1, $\underline{+1}$	190 pm	+1: 116 pm	1st: 495.8	2nd: 4562	3rd: 6910.3
Potassium	19	[Ar] $4s^1$	0.82	−1, $\underline{+1}$	243 pm	+1: 152 pm	1st: 418.8	2nd: 3052	3rd: 4420
Magnesium	12	[Ne] $3s^2$	1.31	0, +1, $\underline{+2}$	145 pm	+2: 86 pm	1st: 737.7	2nd: 1450.7	3rd: 7732.7
Calcium	20	[Ar] $4s^2$	1.00	+1, $\underline{+2}$	194 pm	+2: 114 pm	1st: 589.8	2nd: 1145.4	3rd: 4912.4
Strontium	38	[Kr] $5s^2$	0.95	+1, $\underline{+2}$	219 pm	+2: 132 pm	1st: 549.5	2nd: 1064.2	3rd: 4138
Vanadium	23	[Ar] $3d^3$ $4s^2$	1.63	−3, −1, 0, +1, $\underline{+2}$, $\underline{+3}$, $\underline{+4}$, $\underline{+5}$	171 pm	+2: 93 pm +3: 78 pm +4: 72 pm +5: 68 pm	1st: 650.9	2nd: 1414	3rd: 2830
Iron	26	[Ar] $3d^6$ $4s^2$	1.83	−4, −2, −1, 0, +1, $\underline{+2}$, $\underline{+3}$, +4, +5, +6, +7	156 pm	+2: 75 pm (ls) +2: 92 pm (hs) +3: 69 pm (ls) +3: 78.5 pm (hs)	1st: 762.5	2nd: 1561.9	3rd: 2957
Cobalt	27	[Ar] $3d^7$ $4s^2$	1.88	−3, −1, 0, +1, $\underline{+2}$, $\underline{+3}$, +4, +5	152 pm	+2: 79 pm (ls) +2: 88.5 pm (hs) +3: 68.5 pm (ls) +3: 75 pm (hs)	1st: 760.4	2nd: 1648	3rd: 3232
Copper	29	[Ar] $3d^{10}$ $4s^1$	1.90	−2, 0, $\underline{+1}$, $\underline{+2}$, +3, +4	145 pm	+1: 91 pm +2: 87 pm	1st: 745.5	2nd: 1957.9	3rd: 3555
Zinc	30	[Ar] $3d^{10}$ $4s^2$	1.65	−2, 0, +1, $\underline{+2}$	142 pm	+2: 88 pm	1st: 906.4	2nd: 1733.3	3rd: 3833

* Underlined bold numbers: the usual number of valence electrons gained or lost by an atom under natural conditions.

** ls: low spin; hs: high spin.

Table 2

Interactions between biometal ions and immune cells.

Element classification	Ion	Innate immune cell			Adaptive immune cell	
		Neutrophil	Macrophage	NK cell	T lymphocyte	B lymphocyte
Alkali metal	Lithium		M2 polarization [155]	Proliferation [157]	Proliferation [158]	Cell activity [155]
	Sodium		Signal transduction, cytokine production [169]		Phenotype differentiation [169]	
	Potassium			Function [187]	Activation [185]	Proliferation [188]
Alkaline earth metal	Magnesium		M2 polarization [224]		Cell metabolism, signal transduction [228,229]	
	Calcium				Cytokine production, phenotype differentiation [251,252]	
Transition metal	Strontium	N2 polarization [267]	M2 polarization [268,269]	Function [265]		
	Vanadium	ROS production [277]			Function [279]	
	Iron		Phonotype polarization [305]		Differentiation, cell activity [305]	
	Cobalt	Signal transduction [314]	Phonotype polarization [316,318]			
	Copper	Proliferation, function [352]	M1 differentiation [316,352]		Proliferation, cytokine production [332]	
	Zinc	Chemotaxis, phagocytosis, and cytokine production [364]	Signal transduction [358]	Differentiation, proliferation [359]	Differentiation, proliferation [368]	Proliferation, signal transduction [370]

ment of B cell activity [155]. Li$^+$ inhibits GSK3 production and increases the production of β-catenin involved in the Wnt pathway to drive T cell proliferation [158]. Lithium ions exhibit distinct immunomodulatory effects on immune cells within both immune systems. An overview of the immunological regulatory properties of lithium ions, as well as other subsequent ions, can be found in Table 2.

4.1.1.3. Osteogenic effects of lithium. Studies validated the bone-protective function of the lithium ions [159]. Fig. 5c illustrates the regulatory role of lithium ions in osteoblastic-specific gene expression through signal pathways, which include the canonical Wnt/β-catenin pathway, BMP-2 signal pathway, and the PI3K/Akt pathway. Fig. 5d shows signal pathways of M-CSF, mitogen-activated protein kinase (MAPK), RANK/RANKL/OPG, NF-κB, and calcium signaling, which regulate osteoclast-specific gene expressions by lithium ions [159]. After being cultivated with Li$^+$, osteoblast precursor cells, and osteoblasts progressively released osteoblast development markers, including ALP, Runt-related transcription factor 2 (Runx-2), OCN, and

collagen-1 [160]. Zhang J. et al. examined the ossification by bone marrow stromal cells (BMSCs) cocultured with lithium-doped nanosphere-containing materials [161]. Their results indicated that several genes, such as ALP, Runx-2, ALP, OCN, and OPN increased, suggesting that a Li$^+$ enriched environment had a beneficial influence on the development of osteoblastic cells. Loiselle et al. created a femur fracture model using connexin43 (Cx43) conditional gene knockout mice [162]. The Cx43 is extensively expressed in the bone-to-link bone matrix, hence Cx43-deficient animals with fractures had delayed union. Arioka et al. applied GSK-3 inhibitors LiCl and Li$_2$CO$_3$ in vitro and in vivo, respectively. The results illustrated that LiCl promoted osteoblast differentiation, and the application of Li$_2$CO$_3$ accelerated bone regeneration within local tibial bone defects of rats [163]. Pepersack et al. demonstrated that lithium ions reduced the resorption of fatal long bones via modulating parathyroid hormone (PTH) and prostaglandin E2 (PGE2). It has a full-blocking effect on vitamin D3-induced osteogenesis [164]. Lithium ion may be a potential factor for bone regeneration; however, inflammatory effects must be closely controlled. Table 3 lists the names

**Fig. 5. Properties of lithium ion.** (a) Ion channels and transporters of lithium ions on different cell membranes. Adopted from ref. [153], copyright 2023, Springer Nature. (b) Schematic diagram of the differentiation and response of immune cells in a healthy state or immunomodulation by lithium salts. Adopted from ref. [158], copyright 2023, Elsevier. (c) Schematic diagram showing the regulatory response of lithium ions in the osteoblastic-specific gene expression through three major signaling pathways. Adopted from ref. [159], copyright 2020, Frontiers Media S.A. (d) Schematic diagram showing the regulatory response of lithium ions in the osteoclastic-specific gene expression. Adopted from ref. [159], copyright 2020, Frontiers Media S.A.

and applications of lithium ion and other bioactive metal ions-related biomaterials.

4.1.2. Sodium

4.1.2.1. physicochemical and physiological properties of sodium. Sodium, also referred to as natrium (Na), has an atomic number of 11. It is char-

acterized by an atomic radius of 186 pm, an ionic radius of 116 pm, and a covalent radius of 166 ± 9 pm. Like lithium, sodium readily ionizes, shedding one ion. Sodium homeostasis is of critical importance to organisms, as sodium and potassium ions maintain the osmotic pressure of the intracellular and extracellular fluid, regulating the membrane potential to ensure normal cell functions. It is the dominant cation in the

Table 3
Biometallic ion-related materials and their functions.

Element classification	Ion	Biometallic ion-related materials	Functions
Alkali metal	Lithium	Li$^+$ doped mesoporous silica nanospheres (LMSNs) [161]	Osteogenesis [161]
	Potassium	Kappa-carrageenan/chitosan/gelatin +KCl (KCG-KCl) [192]	Osteogenesis [192]
Alkaline earth metal	Magnesium	1. Magnesium-calcium phosphate cement (MCPC) [235] 2. Porous PLGA/TCP/Mg (PTM) scaffold [237] 3. PLGA/Mg-GA MOF scaffold [230] 4. Ultrapure magnesium pin [239]	1. Osteoimmunomodulation, osteogenesis, angiogenesis [235] 2. Osteogenesis, angiogenesis [237] 3. Osteogenesis, angiogenesis, anti-inflammation [230] 4. Neural regulation of osteogenesis [239]
	Calcium	1. β-Tricalcium phosphate (TCP) [261] 2. Hydroxyapatite (HA) [256] 3. HA nanoparticles (n-HA) [260]	1. Osteogenesis [261] 2. Immunomodulation, angiogenesis, osteoclastogenesis, osteogenesis [256] 3. Antitumor effect, osteogenesis [260]
	Strontium	1. Sr-crosslinked RGD with alginate hydrogel [268] 2. Sr-incorporated micro/nano titanium (SLA-Sr) [271]	1. Osteogenesis, anti-osteoclastogenesis, immunomodulation [268] 2. Immunomodulation, angiogenesis, osteogenesis [271]
Transition metal	Vanadium	Mesoporous bioactive glass doped Vanadium (V-MBG) [281]	Osteogenesis [281]
	Iron	Iron-matrix composites with silicate-based bioceramic particles [308]	Osteogenesis [308]
	Cobalt	1. Cobalt-doped bioactive borosilicate glass scaffolds [320] 2. Tricalcium phosphate scaffolds with cobalt (Co-TCP) [321]	1. Osteogenesis, angiogenesis [320] 2. Osteogenesis, angiogenesis [321]
	Copper	1. Cu-incorporated TCP [348] 2. Cu-containing bioactive glass ceramics (Cu-BGC) [340] 3. Implant surface self-assembled copper nanoparticles (CuS NP) and reduced graphene oxide (rGO) [347] 4. Copper containing bioactive glass [350]	1. Immunomodulation, Osteogenesis, angiogenesis, anti-osteoclastogenesis [348] 2. Osteochondral regeneration, anti-inflammation, immunomodulation [340] 3. Antibacterial, osteogenesis [347] 4. Antibacterial, osteogenesis, angiogenesis [350]
	Zinc	1. Zn-MEM [376] 2. Zinc silicate/nanohydroxyapatite/collagen (ZS/HA/Col) [377]	1. Osteogenesis [376] 2. Osteogenesis, angiogenesis, immunomodulation [377]

extracellular fluid regulated by a group of ion channels, transporters, and proteins on the cell membrane or within the cell. For instance, the Na$^+$/H^+ exchanger-3 (NHE-3) functions as an indirect Na$^+$ and HCO^{3-} reabsorption channel [165]. The Na$^+$/K^+-ATPase specifically selects K^+ and Na$^+$ while allowing other ions to flow through the pump. The pump consumes adenosine triphosphatase (ATP) to export 3 Na$^+$ and import 2 K^+ to generate an electrochemical gradient [166]. The Na$^+$/K^+-ATPase maintains a sodium concentration ratio of 1:10 between the intracellular and extracellular environments of the cell so that its activity remains stable [166]. Fig. 4 represents the transporters and channels on immune cells.

Additionally, a protein named glycosaminoglycans (GAGs) permits Na$^+$ to bind due to its negative charge, leading to non-osmotic behavior in the microenvironment and assisting in the redistribution of Na$^+$ in the local area. Disruption of sodium balance in humans can lead to hypernatremia (water loss) or hyponatremia (water absorption), which disrupts osmoregulation and causes severe dysfunction of multiple systems [167]. Overconsumption of sodium can damage the immune barriers and the defense functions of immune cells and immune organs, resulting in an imbalance of immune responses (Fig. 6a). The accumulation of Na$^+$ in the skin promotes vascular endothelial growth factor C (VEGFC) release and nitric oxide (NO) [168].

4.1.2.2. Immunoregulation of sodium. Overdose of Na$^+$ intake can seriously impede the function of immune cells and target organs [166]. Fig. 6c illustrates changes in both the classical pathway of pro-inflammatory macrophage activation and the alternative pathway of anti-inflammatory macrophage activation under high NaCl conditions [169]. Classically activated macrophages express inflammatory cytokines such as TNF, IL-6, and IL-1β via the NF-κB and AP1 pathway, and then release NO via NOS2. In a high NaCl environment, signals upregulate the nuclear factor of activated T cells 5 (NFAT5) and heterodimeric

transcription factor AP1 through the p38 pathway. This increases the production of NO and TNF beyond normal levels, exacerbating inflammation. Additionally, NaCl activates inflammasomes: NOD-like receptor thermal protein domain associated protein 3 (NLRP3) and NLRP4, which induce subsequent Caspase 1 activation and ultimately IL-1β production. These signaling pathways lead to a more inflammatory environment, thus enhancing pathogen clearance and Th17 cell differentiation through the upregulation of IL-1β. Alternatively activated macrophages, known for their tendency to produce anti-inflammatory cytokines, can suppress the expression of STAT6 by inhibiting the AKT-mTOR signaling pathway. This regulatory effect is also implicated as a contributing factor in delayed wound healing. In Fig. 6d, the polarization of Th17 and Treg cells in a high NaCl microenvironment is depicted. IL-23 and its receptor IL-23R are inhibited by the transcription factor FoxO1 through the RORγt pathway. In a high salinity environment, extracellular sodium ions enter Th17 cells and inhibit the activity of FOXO1, which allows RORγt to produce more IL-23R and promotes Th17 cell differentiation. In contrast, Treg cells are affected by a high sodium ion environment, losing their normal regulatory function and transforming into a Th1-like morphology. In a high salt environment, sodium mediates the production of the serum/glucocorticoid-regulated kinase 1 (SGK1) and inhibits its normal function by phosphorylating FOXO1 and FOXO3, thereby reducing the stability of FOXP3. Following this process, salt-stimulated Treg cells reduce IL-10 and TGF-β production, generate IFN-γ, and adopt a Th1-like phenotype [169].

4.1.2.3. Effects of sodium on bone tissue regeneration. Orthopedic implant materials containing sodium, especially alginate hydrogel, are frequently used in bone repair. However, abnormal local concentrations of Na$^+$, whether too high or too low, can negatively impact the healing of bone defects. Evidence suggests that chronic hyponatremia (low sodium levels) is linked to fractures, particularly in the elderly population. This

Fig. 6. Properties of sodium ion. (a) Schematic diagram of high salt (sodium chloride) diet disturbing the function of local barriers, immune cells, and epithelial cells of organs (skin, lung, kidney, central nervous system, and gut), and subsequently influencing the balance of immune responses. Adopted from ref. [168], copyright 2019, Springer Nature. (b) Flowchart illustrating how hyponatremia induces osteoclast formation and inhibits osteoblasts, hence reducing bone strength. Adopted from ref. [171], copyright 2016, Springer Nature. (c) Conceptual diagram showing macrophage differentiation in response to a high salt environment. Adopted from ref. [169], copyright 2019, Springer Nature. (d) Conceptual graph of a propensity for naive T cells to polarize into either Th17 cells or Treg cells under high salt conditions. Adopted from ref. [169], copyright 2019, Springer Nature.

ARTICLE IN PRESS

JID: ENGREG [m5GeSdc;February 1, 2024;14:5]

S. Liu, Z. Lin, W. Qiao et al. Engineered Regeneration xxx (xxxx) xxx

may be due to hyponatremia causing mild cognitive impairment, leading to gait instability and falls, or it may directly cause osteoporosis by mobilizing sodium stores in bone tissue. Additionally, low extracellular sodium stimulation can stimulate osteoclast formation as well as bone resorption (Fig. 6b) [170–172]. High sodium intake is a recognized risk factor for osteoporosis. Cui et al. illustrated that ovariectomized rats fed a high-salt diet showed disruption in bone microarchitecture and increased urinary calcium excretion. At the same time, the expressions of sodium channel ENaCα and voltage-gated chloride channel ClC-3 were up-regulated, while the expressions of sodium-chloride cotransporter (NCC) and sodium-calcium exchanger (NCX1) were down-regulated in epithelial cells [173]. Although no direct evidence shows that degraded hydrogels or other sodium-containing materials hinder bone regeneration, the impact of changes in sodium concentration on bone suggests that the accumulation of sodium ions through a long-term utilization of these materials should not be overlooked [174–176].

4.1.3. Potassium

4.1.3.1. physicochemical and physiological properties of potassium. Potassium (K) is the second most abundant alkali metal element in humans. It possesses an atomic radius of approximately 227 picometers (pm), an ionic radius of around 152 pm, and a covalent radius of approximately 203 ± 12 pm. These measurements provide the spatial distribution and size of potassium atoms or ions in various physiological contexts. Potassium is prone to losing its outermost electron to form potassium ions. Fig. 7a illustrates the measurement and process of potassium uptake, exchange in the body, and excretion [177]. The concentration of K^+ within the cell, which ranges from 140 to 150 mmol/L, is significantly higher than in the extracellular matrix ranging from 3.5 to 5.5 mmol/L [178]. This vast disparity is maintained by K^+ channels, which monitor and control the flow of K^+. This transfer of K^+ across the cell membrane balances fluctuations in electric potential and is key to the function of muscular, neuronal, and cardiovascular cells [179]. In addition, K^+ is largely involved in physiological activities, such as hormone secretion, maintenance of blood pressure homeostasis, gastrointestinal motility, nutrient metabolism, and water-electrolyte balance.

4.1.3.2. Potassium ion channels. There are two types of K^+ channels: Passive K^+ leak channels and active ion transport channels of Na^+/K^+-ATPase (Fig. 7b) [180]. Passive transport involves the movement of potassium ions, facilitated by the cell membrane's permeability and ionophore proteins. On the other hand, active transport is an ATP-dependent mode, typically involving Na^+/K^+-ATPase pumps. These pumps transport potassium ions from a low concentration region (the extracellular environment) to a high concentration region (the intracellular environment), thus creating a high-potassium environment within cells [181].

4.1.3.3. immunoregulation of potassium. Potassium ions and their regulation via potassium ion channels are vital for immune cell functions [182]. The K^+ concentration within immune cells is regulated by voltage-gated channels: (Kv1.3, Kv1.5), calcium-dependent channels, calcium-activated K^+ channels (KCa3.1, KCa1.1, IKCa1), and calcium release-activated channels (CRAC) [183,184]. T cells are influenced by nearby dying cells, which release more potassium ions into the microenvironment. This increased influx of K^+ into T cells via pump or leak channels inhibits T cell activation and tumor-killing ability by suppressing protein phosphatase 2A (PP2A), and Akt and mTOR protein kinase-related signaling pathways (Fig. 7c). Kv1.3 is the predominant subset of Kv channels in resting T cells, while IKCa1 is dominant in activated T cells. The apoptosis of T cells may be governed by the loss of intracellular K^+ via Kv1.3 channels [185]. Macrophages have been found to express K^+ channels (Kv1.3, Kv1.5, KCa1.1), which could serve as drug binding sites for altering their phenotypes [186]. The membrane of NK cells contains Kv1.3 channels, and the inhibition of non-specific Kv channels reduces the cytotoxicity of NK cells [187]. Memory B cells expressed

around 2500 Kv1.3 channels at rest, with expression increasing upon activation [188].

4.1.3.4. Effects of potassium on bone tissue regeneration. Potassium supplementation may promote bone formation. In a clinical study of the relationship between potassium content consumption and bone mineral density (BMD), researchers divided the enrolled population into three groups according to dietary potassium intake, and people with higher dietary potassium intake showed higher BMD [189]. In exploring the mechanism of BCP in promoting osteoinduction, researchers discovered that BCP induced PP2A upregulation to dephosphorylate and prevent endocytosis of the Na^+/K^+-ATPase, thereby maintaining its activation. Activating Na^+/K^+-ATPase of mouse MSCs enhanced osteogenic gene expression and calcium deposition, improving osteogenesis [190]. Few studies have directly applied potassium ions as the major component of bone tissue engineering materials. However, potassium ions can exhibit distinctive physical and chemical properties from sodium ions in materials [191]. A 3D scaffold composed of Kappa-carrageenan, chitosan, and gelatin crosslinked with potassium chloride (KCl) was prepared for bone tissue regeneration. Compared to scaffolds without crosslinked KCl, this material demonstrated superior mechanical properties and osteogenic differentiation potential [192].

### 4.2. Alkaline earth metals

Alkaline earth metals make up six elements in group 2 of the periodic table: beryllium (Be), magnesium (Mg), calcium (Ca), strontium (Sr), barium (Ba), and radium (Ra). These metals show a tendency to lose electrons and thus form doubly charged positive ions because their outer S-orbitals accommodate two electrons [151]. In their respective periods, they possess the second lowest first ionization energy of elements, which is mainly attributed to their low effective nuclear charge and their ability to achieve a stable outer shell configuration via losing these two electrons [151,195]. With the exception of beryllium, all alkaline earth metals can react with halides to formulate alkaline earth metal halides, or with water to form strongly alkaline hydroxides.

These elements' relatively stable atomic orbital structure and ionic properties allow them to play a regulatory character in organisms. Deficiency of certain metal components, such as magnesium, calcium, and strontium, can induce diseases [196]. Hypomagnesemia, characterized by a decreased level of magnesium in the blood, is common in the general public, accounting for 2.5% to 15% of cases. Most patients are asymptomatic with hypomagnesemia, but symptoms of neuromuscular, cardiovascular, and metabolic dysfunction can occur [197]. Magnesium sulfate has been applied in the relief of rapid atrial fibrillation and for pain relief [198,199]. Since calcium is required for bone development, many bone-related diseases are associated with organic calcium matrices and hydroxyapatite (HA) in bone structures or tissues [200]. Conditions such as osteoporosis require additional calcium supplementation to treat the loss or deficiency of calcium, and the treatment of fractures also involves calcium supplementation to support bone formation [201]. For pharmaceutical applications, absorbable calcium compounds are more beneficial for the treatment of these diseases [202,203]. Strontium ranelate has demonstrated the potential to enhance bone growth and BMD. However, it is important to note that it can also lead to a decline in the calcium ratio within bone. The long-term biological effects of strontium ranelate are still under investigation and require further study to fully understand its comprehensive impact [204,205].

4.2.1. Magnesium

4.2.1.1. physicochemical and physiological properties of magnesium. Magnesium ion (Mg^{2+}) is the fourth most abundant cation in humans, following calcium, potassium, and sodium ions [206]. The atomic radius of magnesium is approximately 160 pm, while its ionic radius is around 86 pm. In terms of covalent radius, magnesium has a value of 141 ± 7 pm. It typically loses two electrons to form a stable magnesium divalent

Fig. 7. Properties of potassium ion. (a) Schematic representation of the overall intersection of potassium uptake, flow, and excretion between organs. Adopted from ref. [177], copyright 2020, The American Physiological Society. (b) Scheme of Na/K-ATPase with α-subunits and cardiac glycosides. Adopted from ref. [193], copyright 2017, Frontiers Media S.A. (c) **a.** Schematic depicting tumor cells undergoing necrotic cell death releasing a high level of K^+ into the microenvironment, which contributes to a high intracellular K^+ concentration of T cells. **b.** Scheme of pharmacological stimulation for the overexpression of voltage-gated K^+ channels and calcium-activated K^+ channels, resulting in intracellular K^+ concentration decrease and normalization of T cell function. Adopted from ref. [194], copyright 2016, Springer Nature.

cation (Mg^{2+}). Approximate magnesium storage in the body is about 25 g distributed in organs and tissues, with 65% found in the bone matrix and 32% in macromolecules like nucleic acids, proteins, and lipids [207,208].

Compared to adjacent elements in the periodic table, such as Li, Na, K, and Ca, magnesium has a smaller ionic radius but larger hydration energy than calcium (0.86 vs 1.14 Å for Ca, −1922 vs −1592 kJ/mol, respectively) [206]. In the structure of hydrous $MgSO_4$ or $MgCl_2$, magnesium ions are bound to 6 or 7 molecules of H_2O, respectively, whereas calcium and beryllium ions, in the case of $CaCl_2$ or $BaCl_2$, are coordinated to 2 or 1 mol of H_2O, respectively [206]. $Mg-H_2O$ coordination yields a typical octahedral conformation and exhibits a slower rate of exchange of H_2O molecules than other metal ions. This phenomenon makes magnesium have a larger occupancy and more stable biological properties in the organism [206]. Additionally, the hydrated radius of a magnesium ion is approximately 400 times greater than its dehydrated radius. This significant difference in size necessitates energy to dehydrate the ion before it can pass through channels and transporters. Consequently, this size disparity can hinder the potential functional role of magnesium ions in signal pathways [209].

At the cellular level, magnesium exerts profound regulatory effects on biological processes, encompassing cell proliferation, differentiation, and survival. It serves as a cofactor or activator with multiple enzymes in DNA and RNA synthesis, amino acid metabolism, as well as the intricate pathways governing sugar, protein, and lipid metabolism. Magnesium's involvement in these fundamental cellular processes underscores its indispensability for maintaining optimal cellular function, ensuring proper cellular growth and development, and facilitating the intricate interplay of metabolic pathways essential for cellular homeostasis [210]. Magnesium is a structural component of numerous biological macromolecules in stabilizing and modifying structures [211]. Additionally, magnesium is involved in energy metabolism by forming the Mg-ATP2 complex or regulating ATP distribution through the modulation of ATP-Mg/Pi carrier activity [212]. It can also act as a second messenger to transduce cell signals, mediate downstream molecule activation, and neural regulation [213], and regulate cell apoptosis [214]. In addition, magnesium ions influence ion stability of cell membranes, including regulation of ion channel activity, and resistance of calcium ions [215].

4.2.1.2. Magnesium transporters. Studies have illustrated numerous magnesium transporters on the cell membrane [216]. Magnesium transporter 1 (MagT1) is widely expressed in human cells and selectively transports Mg^{2+} with voltage-dependent and pH-dependent inward currents [217]. It has profoundly been found that immune cells (typically B and T cells) express MagT1 (spleen and thymus), mediating magnesium ion metabolism and signaling transduction [218]. SLC41A1 and SLC41A2 are part of the human solute carrier (SLC) family, which comprises over 300 transporters and more than fifty subgroups of membrane transport proteins [219]. The TRPM family is a significant part of transient receptor potential (TRP) channels, which include TRPM1-TRPM8, and are widely expressed on cells [219]. These channels participate in cellular regulatory processes, such as proliferation, metastasis, invasion, and death [220]. Among them, transient receptor potential cation channels M6 (TRPM6) and M7 (TRPM7) are characteristic, as they both possess ion channels and are permeable to Mg^{2+}, Zn^{2+}, and Ca^{2+} [221]. Studies have shown that these two channels regulate Mg ions at a cellular level, and mutations in their genes can cause diseases related to magnesium ion metabolism [222].

4.2.1.3. Immunoregulation of magnesium. Magnesium has a profound impact on the immune system, influencing a group of immune cells and mediating cell proliferation, metabolism, subtype changes, and cell death in conjunction with the above mentioned magnesium-ion-related channels [223]. Fig. 8d illustrates the magnesium transporters of immune cells and their roles in immune-receptor signaling. Magnesium signals can mediate the opening process of calcium (Ca^{2+}) channels in the

endoplasmic reticulum (ER), leading to the release of Ca^{2+} into the cytoplasm and the influx of Ca^{2+} into CRAC channels. Magnesium-related channels, including MagT1, TRPM6/7, and SLC41A1/A2, are significant channels in immune cells that regulate the transport of magnesium ions in the intracellular and extracellular environment [216]. In bone marrow-derived macrophages, high TRPM7-like currents were detected due to Mg^{2+} regulation, which increased the amount of the cytokine IL-43. applying TRPM7 blockers (NS8593 and FTY720) resulted in a decline in cell proliferation, cytokine release, and the formation of M2 type macrophages [224]. Individuals with insufficient TRPM6 were found to be susceptible to seizures or even death in the absence of Mg^{2+} [225]. In experiments with human Jurkat T cells, biphasic Mg^{2+} dose-response curves were observed in the absence of TRPM7 current [226]. Magnesium via TRPM7 induces M2 subtype polarization of macrophages and promotes osteogenesis in the early stage of the experimental period [227]. A particular X-linked human immunodeficiency disease characterized by CD4 lymphocytopenia is caused by a congenital deletion of the MagT1 gene, leading to an insufficiency of magnesium influx associated with the engagement of antigen receptors upon $CD4^+$ T cells. This discovery underlines the role of magnesium ions as second messengers [228]. Recent research indicated that tumor cells can inhibit the typical killing capabilities of activated $CD8^+$ T lymphocytes by accumulating Mg^{2+} and blocking its normal metabolism, thereby proliferating and evading the immune system [229].

4.2.1.4. Osteogenic effect of magnesium. Magnesium ions have been extensively investigated in osteogenesis, angiogenesis, and anti-inflammatory processes. This has led to the exposure of innovative bone regeneration materials [230–234]. Several magnesium-based materials have been developed, leveraging the osteogenic effects of magnesium. For instance, a magnesium-containing calcium phosphate cement was proposed by Wang M. et al. They observed that the secretion level of TNF-α and IL-6 decreased when macrophages were cultured with extracts of magnesium-calcium phosphate cement (MCPC), while the expression of bone repair-related cytokine TGF-β1 increased [235]. It was also found that the influence of Mg^{2+} on macrophages is dose-dependent, with higher concentrations (20 mM) inhibiting macrophage polarization toward M1 more effectively than lower concentrations (5–10 mM) [236]. This demonstrated that Mg^{2+} might participate in the application of novel materials regulating osteogenesis and the immune response. Further, a PLGA/Mg-GA MOF scaffold was synthesized. When implanted into the defective site, the scaffold was phagocytosed by adherent cells, releasing exosomes, Mg^{2+}, and gallic acid (GA), enhancing osseointegration, angiogenesis, and anti-inflammatory ability [230]. Another study reported a porous PLGA/TCP/Mg (PTM) scaffold for bone defect repair. PTM increased blood perfusion and promoted neovascularization seen at 8 weeks after operation. After 12 weeks, PTM significantly promoted new bone formation and improved its mechanical properties [237].

Magnesium has also been reported to improve osteogenesis in an osteoimmunological manner. Following different stages of the bone healing process, Mg^{2+} regulates cytokine production by monocytes/macrophages and thereby influences the metabolic balance of osteoblasts and osteoclasts. Fig. 8c illustrates the process of Mg-mediated immune response regulating bone remodeling at the cellular and subcellular levels. In this process, magnesium ions enter cells through the TRPM7 channel, mediating the release of M7CK protein to promote the phosphorylation of H3S10, thereby promoting the transcription of inflammatory genes [227]. In another study, it was observed that magnesium exerted inhibitory effects on macrophage activation. This was evident by a notable reduction in the proportion of CCR7-positive cells, whilst the decrease of CD206-positive cells was comparatively less pronounced [238].

Based on the good osteogenic effect of Mg based materials, some articles have carried out in-depth research and discussion on the related mechanism of osteogenesis. Zhang et al. tested an ultrapure magnesium

Fig. 8. Properties of magnesium ion. (a) Schematic diagram of Mg^{2+} involved in enzyme metabolism, energy conversion, macromolecular structure formation, signal transduction, and ion metabolism, ultimately affecting cell proliferation, differentiation, and survival. Adopted from ref. [240], copyright 2021, Elsevier. (b) Schematic of implant-derived Mg^{2+} entering DRG neurons via magnesium transporters or channels, promoting calcitonin gene-related peptide (CGRP) vesicles release and activating CGRP receptors within the periosteum, leading to osteogenesis-related genes expression. Adopted from ref. [239], copyright 2016, Springer Nature. (c) Schematic of macrophages and MSCs involving in the whole stages of bone repair process regulated by Mg^{2+} (left panel) and the process of magnesium entering cells through ion channels: CXC chemokine receptor 1/2 (CXCR1/2) and TRPM7, and participating in the transcriptional regulation of inflammation-related genes under the microstructure (right panel). Adopted from ref. [227], copyright 2020, Springer Nature. (d) Symbolized schematic diagram of different types of receptors, transporters, and channels on the ER, inner mitochondria, and plasma membrane of an immunocyte, and the range of Mg^{2+} concentrations in each part. Adopted from ref. [216], copyright 2012, Springer Nature.

pin in a rat model. The findings revealed a noteworthy occurrence of new bone regeneration in the cortical bone following the implantation. The increased presence of extracellular magnesium ions in ipsilateral dorsal root ganglion (DRG) neurons stimulated MagT1-dependent and TRPM7-dependent entry of magnesium ions, leading to an elevation in intracellular ATP levels and the terminal synaptic vesicles accumulation [239]. Mg ions via MagT1 or TRPM7 regulated vesica releasing at the DRG nerve ending and alter gene expression contributing to osteogenic differentiation (Fig. 8b). A study reveals a biphasic action pattern of Mg ions in bone regeneration [227]. Mg ions upregulated TRPM7 at the early stage of inflammation and promote TRPM7-dependent Mg^{2+} ion influx into the mononuclear-macrophage lineage. In the advanced phase of osteogenic healing, the prolonged presence of magnesium ions has been found to have detrimental effects. It can excessively activate the NF-κB signal pathway among macrophages, which in turn leads to an increased formation of osteoclast-like cells.

4.2.2. Calcium

4.2.2.1. physicochemical and physiological properties of calcium.
Calcium is an alkaline earth metal known for its active nature with an atomic radius of 197 pm, an ionic radius of 114 pm, and a covalent radius of 176±10 pm. Calcium and magnesium belong to the same main group, sharing some basic chemical properties. Calcium has two easily losable valence electrons in its outermost *s*-orbital, making it prone to form a dipositive ion (Ca^{2+}) under most conditions. Calcium ions are among the most prevalent metal ions in humans, as a second messenger in regulating the proper functions of organs and body cells [151,241]. Ca^{2+} signaling regulates physiological processes such as blood clotting, nerve transmission, heart rhythm, and muscle contraction and relaxation (Fig. 9a). At the cellular level, calcium acts as a component of proteins and enzymes to maintain protein conformation stability and exert biological effects. Some proteins can bind calcium ions directly or chelate calcium ions with amino acid residues, including trypsin, osteocalcin, osteopontin, and bone sialoprotein [151]. Calcium regulation in vivo is controlled by thyroid hormones, and calcitonin is used to maintain calcium homeostasis in the human body [242].

4.2.2.2. Calcium transporters.
Calcium ion channels and transporters control Ca^{2+} homeostasis. Typically, a specific cell type selects a distinct combination of channels that suits its biological roles. For instance, as lymphocytes polarize and activate, both the type and content of calcium channels on T cells change. The expression of calcium release-activated calcium modulator 1 (CRACM1), CRACM2, and CRACM3 on mouse double-positive lymphocytes changes as they develop into CD4^+T cells. Meanwhile, its STIM2 expression changes from negative to positive. Human lymphocytes show similar characteristics with CRACM1 and CRACM3 expression increasing in response to CD4^+T cell activation [243]. Fig. 9d summarizes the channels on lymphocytes that control the flux of calcium ions. On the plasma membrane, the types of channels involved in calcium transfer include SOCE, transient receptor potential channel 1 (TRPC1) (whose categorization as either SOCE or ROCE is not yet determined), non-store-operated channels, and ion exchangers. On the ER membrane, the calcium release channel, calcium pump, and STIM1 (the sensor of stored calcium) all participate in calcium transport. Calcium ion exchangers and Ca^{2+} uptake channels are shown on the mitochondrial membrane [243]. Calcium ion channels are divided into store-operated Ca^{2+} channels (SOCCs) and non-store-operated Ca^{2+} channels. SOCCs are widely observed in signaling transport in response to the "store-depletion" effect, representing the biological effects of calcium storage and release to the cytoplasm from ER [244]. CRAC channels are expressed on lymphocytes and serve as a member of the SOCC channel family. Non-store-operated Ca^{2+} channels, including P2 receptors, TRPV6, TRPM2, TRPM7, CARC channels, Ins(1,4,5)P3R, voltage-operated Ca^{2+} channels (Cav) as well, primarily facilitate non-selective cation influx. In addition, some indirect channels also control the balance of calcium ions. Operated by calcium pumps, Ca^{2+} can be pumped

out of the cell to maintain a balance of Ca^{2+} concentrations in the extracellular fluid (about 1 mM) and the ER (about 100 nM) [245]. These calcium channels, pumps, and receptors interact with each other to maintain the functional integrity of cell signaling.

4.2.2.3. immunoregulation of calcium.
Calcium is regulated by ion channels in immune cells and influences downstream signal transduction, leading to changes in gene expression and protein products [246]. CRAC channels manage the intracellular Ca^{2+} increase in lymphocytes [247]. Store-operated Ca^{2+} entry (SOCE), facilitated by the influx of calcium ions (Ca^{2+}) through CRAC channels, exerts profound regulatory influence on T cell dynamics by orchestrating the activation of Ca^{2+}-dependent transcription factors and finely modulating gene expression [248–250]. Beyond its impact on gene regulation, the SOCE-mediated differentiation pathways intricately shape the fate of T cells, steering them towards specific subtypes (Tfh cells, Treg cells) [251]. Fig. 9b visually encapsulates the intricate interplay of SOCE in governing the functional repertoire of conventional and murine regulatory T cells. Although thymus-derived naive T cells appear to be largely unaffected by SOCE, differentiation of peripheral naive T cells into follicular regulatory T cells (Tfr) or induced regulatory T cells (iTreg) unequivocally depends on the fine-tuned orchestration by SOCE. Furthermore, the versatile thymus-derived regulatory T cells (tTregs) demonstrate remarkable plasticity, enabling their differentiation into specialized subtypes of effector regulatory T cells, such as Tfr cells involved in germinal center responses, and tissue-resident Treg cells (tissue Treg) dedicated to the maintenance of tissue-specific organ homeostasis. These intricately modulated T cell subsets serve as pivotal gatekeepers in sculpting immune responses and ensuring immune homeostasis [252].

4.2.2.4. osteogenic effects of calcium.
Calcium is vital for bone development, and many bone diseases are connected to the content of the organic calcium matrix or hydroxyapatite in bone tissue [253,254]. For instance, osteoporosis is defined as a decrease in mineral content per unit volume of bone, often caused by malabsorption, decreased intake, or increased calcium loss [201,255]; Delayed union and non-union, common complications of bone defects, are also closely tied to calcium intake. Given the structure of bone tissue, new implant materials have been developed for treating fractures or bone defects. Hydroxyapatite (HA), which contains a substantial proportion of Ca, has been used in the preparation of surgical implants [256], biological coatings of alloy materials [257], and bone replacement materials [258]. As an essential component of bone tissue, calcium ions are also involved in osteoimmunological processes. Bone extracellular fluid and plasma constantly regulate the balance of calcium ions, which also modulate the bone resorption of osteoclasts to release calcium ions and bone formation of osteoblasts to absorb calcium ions (Fig. 9c) [259]. In a tumor-associated bone defect disease model, researchers used HA nanoparticles (n-HA) to treat bone defects caused by neoplasm metastasis. The n-HA released scaffold showed significant effects in inhibiting tumor growth and osteolytic injury [260]. Additionally, tricalcium phosphate (TCP) has been extensively used due to its capacity to produce RANKL and Wnt signals in osteocytes, which stimulate the differentiation and proliferation of osteoblastic cells [261]. TCP was also found to stimulate macrophage M2 differentiation through the Ca^{2+} sensor receptor, thereby establishing an osteogenic immune microenvironment, inhibiting local inflammation, and promoting bone formation [262].

4.2.3. Strontium

4.2.3.1. physicochemical and physiological properties of strontium.
Strontium (Sr), a member of the mentioned alkaline earth elements above, is highly reactive in its solid metal form when exposed to air and readily reacts with oxide, halides, and sulfide [264]. Strontium possesses an atomic radius of 215 pm, an ionic radius of 132 pm, and a covalent radius of 195±10 pm. Like the preceding two alkaline earth metals, strontium also tends to lose two electrons, forming a stable divalent state. In

Fig. 9. Properties of calcium ion. (a) Scheming diagram of calcium signaling in the regulation of developmental stage and physiological process. During the developmental stage, calcium signaling regulates human egg activation, the occurrence of early embryonic developmental events, the right-left axis patterning of the lung, and the development of organs. In physiological processes, calcium signaling participates in bone formation, thrombosis after trauma, brain function and neurotransmission, and normal contraction of the heart and skeletal muscle. Adopted from ref. [263], copyright 2017, Springer Nature. (b) Scheming diagram of SOCE regulating the agonist-selected Treg cells' development, the production of effector functional cytokines by Th cells, and immunosuppressive molecules produced by Treg cells. Adopted from ref. [252], copyright 2020, Elsevier. (c) Schematic diagram of the interaction and balance of Ca^{2+} in bone tissue and in the extracellular matrix fluid. Calcium concentration mediates the functions of bone cells to maintain the strength and normal volume of bone mass. Adopted from ref. [259], copyright 2020, Springer Nature. (d) Symbolized diagram of Ca^{2+} channels, pumps, exchangers, and receptors on the plasma membrane, ER, and mitochondria membrane. Adopted from ref. [243], copyright 2008, Springer Nature.

the human body, strontium ions can be absorbed and stored in the bone matrix, similar to the storage mechanism of calcium [264].

4.2.3.2. immunoregulation of strontium. The immune system can be influenced by applying Sr^{2+} doped materials or Sr^{2+} therapy in vivo and in vitro, although the precise mechanism remains unclear. From the perspective of immune regulation, it has been shown that Sr^{2+}-treated human large granular lymphocytes (LGL), which include granulocytes and NK cells, significantly increase granulation and reduce killing activities [265]. Strontium-related materials and strontium ions have been demonstrated to polarize neutrophils and macrophages [266]. Tao Li et al. prepared strontium hydroxyapatite (SrHA)-containing nanofibrous gelatin scaffolds. It was shown that strontium induced the immunomodulation and pro-angiogenic functions of neutrophils via the down-regulation of the NF-κB signal pathway and the increase of STAT3 phosphorylation [267]. Another study found that after Sr-doped hydroxyapatite microspheres were implanted into the inflammatory model, the quantity of M2 macrophages in the inflammatory tissue was significantly increased. This indicated that Sr-doped hydroxyapatite microspheres could promote M2 macrophage polarization and regulate inflammatory response [268]. Fig. 10c depicts the antioxidant and immunomodulatory effects of Sr at the molecular and cellular levels, respectively. At the molecular level, strontium inhibits the hydrogen peroxide formation from oxygen with one electron by superoxide dismutase (SOD) and decomposes hydrogen peroxide by catalase (CAT). At the cellular level, strontium induced the transformation of M0 macrophages into the M2 subtype, as well as inhibited the M1 subtype transformation simultaneously [269].

4.2.3.3. osteogenic effects of strontium. Sr-related biomaterials and metals have been used in osteogenesis and show promising application prospects. N.H. Lee et al. prepared a Sr-nanocement for treating osteoporosis [270]. This material significantly increased the osteogenesis-related gene expression: OPN, Bone sialoprotein (BSP), OCN, Runx2, and suppressed osteoclast differentiation (Fig. 10a). Fig. 10b demonstrates the impact of strontium ions on osteoblasts. Strontium can mediate osteoclast apoptosis through the Wnt pathway to promote bone regeneration (Fig. 10b) [24]. A strontium-releasing composite scaffold has been demonstrated to possess osteogenic, anti-osteoclast, and immunomodulatory properties [268]. The expression of ALP from MSC increased, especially under the condition of osteogenesis and higher concentration of Sr^{2+} (1 and 3 mM Sr^{2+}). Regarding osteoclasts, the results indicated that 0.5 mM, 1 mM, and 3 mM of Sr^{2+} drew an inhibition on the ability of osteoclasts to adhere to substrates and incorporate. The Sr^{2+} release from coated titanium enhanced the activities of CAT and SOD, thereby eliminating endogenous reactive oxygen species (ROS) and conferring better osteoinductive and antioxidant properties [269]. Immunologically, Sr^{2+} can also regulate the morphology and CAT/SOD activity of macrophages, promoting the polarization of macrophages from M0 to M2. Another study demonstrated that a stereo lithography Sr-incorporated micro/nano titanium (SLA-Sr) implant released strontium ions into the microenvironment of a bone fracture site, promoting M2 polarization of macrophages, osteogenesis of MSCs and angiogenesis of human umbilical vein endothelial cells (HUVECs) (Fig. 10d) [271].

4.3. Transition metals

Transition metals are characterized by possessing either a partially filled *d* sub-shell or the capability to form cations with an incomplete *d* sub-shell. These elements can be found in groups 3 to 12 on the periodic table. Due to their multivalent nature, transition metals determine their biological effects according to their changes when they exert biological effects in organisms. Under biological conditions, transition metals commonly exhibit two or more oxidation states. For example, compounds of vanadium express various oxidation states between -1 [$V(CO)_6$]$^-$ and $+5$ ($VO_4{}^{3-}$); Iron possesses $+2$ or $+3$ oxidation

states in biological conditions with the function of oxygen transport; copper is commonly found in $+1$ or $+2$ states, helping in the transfer of electrons of Fe proteins. In addition, transition metal ions are usually hydrated by six water molecules arranged in an octahedral formation, which stabilize their chemical and biological characteristics in organisms [272].

4.3.1. Vanadium

4.3.1.1. physicochemical and physiological properties of vanadium. Vanadium is classified in group VB of the periodic table. It is a reactive metal with an atomic radius of 134 pm, and it has four ionic radii depending on its ionic state. Its ionization energy at each stage is not much different, resulting in a great range of oxidation states from -3 to $+7$ in the human body. The polyvalent nature allows vanadium to have fundamental biological effects in the body's fluid environment (Fig. 11a) [273,274]. The $+5$ oxidation state of vanadium is mostly found in extracellular bodily fluids, as represented in anionic metavanadate (VO^{3-}) or orthovanadate anion ($VO_4{}^{3-}$) that resembles phosphates, while the $+4$ oxidation level (VO^{2+}) is predominantly found in intracellular fluid [275]. This suggests that vanadium may substitute phosphates in ATP-driven processes. In a molecule vision, [$VO_4{}^{3-}$] can be transferred into the cell and reduced by glutathione into [VO^{2+}] with an oxidation state of $+4$. This cation, also known as vanadyl, has a similar structure to phosphoric acid and a similar ion radius with Mg^{2+}, therefore potentially competing with them in biological processes, such as ATP phosphohydrolase.

4.3.1.2. immunoregulation of vanadium. The V ions have been found to have immunostimulatory or immune-toxic effects through BCR, TCR, NF-κB pathway, interleukin expression, or TLR (Fig. 11c) [276]. The innate immune system could be influenced by pro-oxidative responses of metal ions. Activated neutrophils, which were treated with vanadium in the distinctive valence states ($+2$, $+3$, $+4$), significantly increased hydroxyl radical formation [277]. CD11c and MHC-II secreted by thymic dendritic cells could be down-regulated by vanadium, thus potentially inducing dysfunction of negative selection of T cells [278]. Vanadium has been found to potentially enhance the function of CD8$^+$ helper T cells. vanadium salts have been observed to express an inhibition on the nuclear factor of activated T cells (NFAT) and impact the constitutive DNA binding activity within resting T cells [279].

4.3.1.3. osteogenic effects of vanadium. Research findings have demonstrated the significant accumulation of vanadium in bones, with levels ranging from 10 to 26 μg/g. Vanadium compounds have shown notable biological effects, including insulin and growth factor mimicking properties, as well as exhibiting osteogenic activity [280]. It has been established that vanadium-based scaffolds are involved in bone metabolism and bone regeneration. A vanadium-doped mesoporous biological glass particle has been prepared to improve osteogenic effects. In cell-based studies, vanadium ions at about 19 μM increased the osteogenic gene: BMP-2, human type I collagen (COL-1), expression, and signaling pathway genes expression: FAK, Itga 2b, pERK1/2. This suggests that vanadium ions could regulate bone regeneration through the Itga 2b–FAK–MAPK pathway (Fig. 11b) [281]. Another study evaluated the osteogenic effect of V and Mg in rats. The combined administration of V-Mg resulted in synergistic effects such as the downregulation of phosphorus and potassium levels in the femoral diaphysis (FD) and the normalization of zinc levels in FD. However, it also presented several antagonistic interactions, including the upregulation of the Na$^+$ level in FD, ALP activity in FD, and femoral bone surface roughness (Fig. 11d) [282].

4.3.2. Iron

4.3.2.1. physicochemical and physiological properties of iron. Iron (Fe) is the fourth most prevalent metal element on Earth and belongs to the first transition series in the periodic table. It is an active metal with a wide range of valence states, an atomic radius of 134 pm, and ions in

Fig. 10. Properties of strontium ion. (a) Schematic diagram of a Sr-BGn nanocement that induces pro-angiogenesis, pro-osteogenesis, and anti-osteoclastogenesis after implantation into an osteoporotic bone defect model. Adopted from ref. [270], copyright 2021, Elsevier. (b) Schematic diagram of the Sr regulation on osteoblasts and osteoclasts (A in the figure), and the proliferation, differentiation, or apoptosis of osteoblasts induced by Sr through multiple signaling pathways (B in the figure). Adopted from ref. [24], copyright 2021, Springer Nature. (c) Schematic diagram of peroxidase pathway at a molecular level and its regulatory role in the phenotypic regulation of macrophages upon high strontium samples. Adopted from ref. [269], copyright 2021, Elsevier. (d) Graphic illustration of SLA-Sr mediating the differentiation of M2 macrophages to promote angiogenesis through local release of Sr^{2+}. Adopted from ref. [271], copyright 2013, Royal Society of Chemistry.

Fig. 11. Properties of vanadium ion. (a) Schematic diagram of vanadium regulating the anabolism of macromolecules and their transformation in mammals. Adopted from ref. [274], copyright 2020, Elsevier. (b) Schematic diagram of activation of osteogenic signaling pathways through culturing MSCs with V-MBG extracts. Adopted from ref. [281], copyright 2013, Royal Society of Chemistry. (c) Simplified Schematic illustrating vanadium regulates the immune response through multiple receptors, signaling pathways, and cytokines. Adopted from ref. [276], copyright 2016, Hindawi. (d) Schematic diagram of correlations of iron and vanadium ions with tested parameters between organs and FD in V exposed rats. Adopted from ref. [282], copyright 2014, Oxford University Press.

each valence state having different ionic radii. The multiple oxidation states of Fe (−4 to +7) make it amphoteric and an excellent electron exchanger [283]. Iron is widely involved in human physiological processes and metabolism [284]. The most common biological iron compounds include hemoglobin, myoglobin, metalloproteins, and transferrin In the human body [285–289]. These iron compounds participate in oxygen transport, enzyme synthesis, electron transfer, and iron absorption [284]. Hemoglobin is an iron-containing oxygen carrier involved in oxygen transport widely presented in red blood cells. Hemoglobin binds oxygen from the lungs and transports it to myoglobin [286]. Myoglobin

uses oxygen to metabolize glucose to produce energy, and hemoglobin combines with carbon dioxide from metabolism to transport it back to the lungs along the veins [289]. Metalloproteins, a class of proteins with metal ion cofactors, include ferritin and erythrocyte membrane redox proteins, involved in the electron transfer of iron ions and the maintenance of Fe^{2+} and Fe^{3+} balance [290]. Many life-essential enzymes contain iron, such as CAT, lipoxygenase, and IRE binding protein (IRE-BP) [291–293]. Transferrin is a protein responsible for the storage and transportation of iron in the body. The center of transferrin has a Fe^{3+}, which is very stable and able to absorb Fe^{3+} efficiently [288].

The process of iron transport in cells can be divided into iron import, storage, and export [294]. Most cells import iron ions mainly through endocytosis mediated by transferrin receptor 1 (TFR1), TFR2, and reduced glyceraldehyde-phosphate dehydrogenase (GAPDH) receptors [295]. The transferrin receptors recognize the trivalent iron bound by transferrin, leading to a conformational change that triggers endocytosis. Within endosomes, iron is subsequently reduced to the ferrous state by reductases. Divalent metal transporter 1 (DMT1) facilitates the iron transportation from the endosome to the cytoplasm. In the cytoplasm, ferrous iron exists in a soluble and chelated state, forming an unstable iron pool with a concentration of approximately 0.001 mM. Iron within this pool is believed to bind to low-affinity compounds (phosphates, peptides, carboxylates) [296,297]; Dysfunctional ferritin may accumulate in the form of hemosiderin, forming an iron storage pool with a much higher concentration than that of the unstable iron pool (0.7–3.6 mM) [298]. Iron export involves the membrane ferroportin expressed on neurons, erythrocytes, macrophages, and enterocytes [299]. It transfers ferrous iron out of the cell assisted by ceruloplasmin and hephaestin [300,301]. Hephaestin occurs only in certain cell types (hepatocytes), and its expression is controlled at the transcriptional level, representing a link between cellular and whole-body iron homeostasis [300].

4.3.2.2. immunoregulation of iron. Iron homeostasis is related to the immunological regulation throughout the whole body. Iron is involved in the physiological activities of cells and the synthesis of biomacromolecules, but it can also produce ROS through the Fenton reaction. While the damaging effect of ROS can help immune cells kill pathogens, the imbalance of iron homeostasis and excessive ROS can damage a variety of autologous biomacromolecules, and eventually affect the normal immune regulation effect of the body [302].

Iron homeostasis is regulated by the hepcidin derived from the liver, which reduces the influx of stored iron into plasma and prevents the absorption of dietary iron by inducing the degradation of the iron-exporting protein ferroportin in its receptor cells (Fig. 12a) [303]. When the body's iron level decreases, iron regulation production decreases along with increased iron absorption. This systemic feedback loop can be disrupted by infection and inflammation, resulting in iron absorption inhibition and inducing iron sequestration in macrophages [304]. This process is also seen as a host defense function, as most microorganisms depend on exogenous iron for survival. Enhanced iron clearance and macrophage sequestration serve a dual function: to deny iron to invading microorganisms and to defend against the toxic effects of elevated iron, hemoglobin, and heme levels. This process ensures that the immune system recognizes and kills pathogens while protecting normal tissues from the damaging effects of elevated plasma iron concentrations caused by ferritin degradation [299].

Macrophage polarization is related to the iron environment. In conditions of iron sufficiency, macrophages typically tend to undergo M1 polarization, while iron deficiency often results in M2 polarization. Iron has been demonstrated in T cell activation and polarization. The uptake of iron is involved through an IL-2-dependent pathway in T cell activation mediated by transferrin receptor 1 (TfR1 or CD71). Mutations in the TfR1 gene can hinder iron endocytosis, resulting in functional deficiencies in T cells. Elevated levels of iron ions can hinder the differentiation and activity of Th1, Th2, and Th17 cells while promoting the differentiation of cytotoxic T lymphocytes (CTLs) (Fig. 12b) [305].

4.3.2.3. Influence of iron on bone homeostasis. Iron homeostasis is important for osteointegration. Iron deficiency can induce hypoxia to induce osteoclast differentiation and inhibit osteoblast differentiation, whereas iron overload produces excessive ROS to damage tissues (Fig. 12c) [303]. Under the precise control of the doses and applications of iron, iron-based materials are produced in an antibacterial way due to their ROS releasing effect [306,307]. Iron based materials have the characteristics of low biodegradation rate and insufficient biological activity. To solve this defect, Iron-based composites containing silicate-based bioceramic particles were prepared [308]. This material solved the former two shortcomings while ensuring the mechanical properties of iron-based materials, and also had certain osteogenic properties.

4.3.3. Cobalt

4.3.3.1. physicochemical and physiological properties of cobalt. Cobalt is a transition metal in the periodic table, located between iron and nickel [151]. Characterized as a ferromagnetic metal, cobalt possesses a magnetic moment between 1.6 and 1.7. Its oxidation states range from +1 to +5, with +2 and +3 being the most common. 58Co and 60Co are two cobalt isotopes that emit high-energy photons and have been extensively used in cancer treatment [151]. Cobalt is regarded as an indispensable element in organisms because it combines with vitamin B_{12} (hydroxocobalamin), which possesses a corrin ring structure and is required by almost all forms of life [310]. Other cobalt proteins, particularly non-corrin cobalt proteins, have attracted profound attention due to their chemical and biological versatility. These proteins, which include methionine aminopeptidase, nitrile hydratase, prolidase, glucose isomerase, and cobalt transporters (COT1), provide new insights into the functions of cobalt beyond its toxicity to the human body and may foster the development of innovative anti-tumor and anti-toxicosis drugs [311]. Additionally, cobalt is a component of the coenzyme of cell mitosis, neurotransmitters, and erythropoietin. However, inorganic forms of cobalt are toxic to humans and have been proven to induce chronic inflammation, excessive bone marrow activity, cardiomyopathy, and even cancer (Fig. 13a) [312].

4.3.3.2. immunoregulation of cobalt. Cobalt ions (Co^{2+}) and Chromium (Cr^{6+}) have been reported to induce apoptosis of T lymphocytes, suppressing their growth and functions [313]. Lawrence et al. pointed out that the TLR4 signaling pathway was directly responsible for the activation of cobalt ions in innate immune cells, with cobalt-induced chemokines having a migratory effect on both neutrophils and monocytes [314]. K. Chamaon et al. proposed that ROS the main toxic substance of cobalt ions. In monocytes, oxygen free radicals and superoxide in the cytoplasm are produced and secreted by the cobalt ions into the immune effector environment, leading to local cell death and tissue damage [315]. Studies have explored the regulation of cobalt ions on macrophage subtype differentiation. the polarization of macrophages can be altered by Co^{2+} depending on its concentration. After treatment with a low medical or high amount of cobalt ions, the phenotypes of macrophages altered into M1/M2 and M1, while a very high dose of cobalt ions led to cell death (Fig. 13b) [316]. One study found that treating macrophages with a high concentration of Co^{2+} for 48 h promoted TNF-α production and exceeded CD206 expression, leading to pro-inflammatory M1 differentiation [317]. In contrast, Kumanto et al. demonstrated that $CoCl_2$ increased M2 subtype differentiation and arginase-1 protein expression, but had no effect under IL-4 and IL-13 conditions, which are potential stimulants for M2 subtype polarization [318]. Co ions have also been reported to promote M1 subtype polarization by activating the iNOS/nitric oxide pathway. Salloum et al. found that Co^{2+} ions stimulated the production of ROS and mitochondrial dysfunction, therefore stimulating an inflammatory response and M1 subtype macrophage polarization [318]. Another study conducted by Yang Xiaoming et al., composed cobalt-incorporated plasma electrolytic oxidation (PEO) coatings featuring varying concentrations of cobalt. The researchers observed that the titanium coatings loaded with cobalt demonstrated pro-inflammatory subtype polarization in macrophages [317]. Xu et al. pointed out that cobalt induces ROS production and reduces RhoA expression (a Rho protein family member). The related RhoA/ROCK pathway has been proven to be involved in osteoarthritis and governs macrophage activities and cytoskeleton structure. This provides a novel method for restricting macrophage spreading, adhesion, and migration and extending chronic inflammation [319].

Fig. 12. Properties of iron ion. (a) Schematic of the homeostatic regulation of iron and iron in the regulation of erythropoiesis and inflammation. Adopted from ref. [309], copyright 2015, Springer Nature. (b) Symbolized Schematic diagram of the regulatory effects of iron on immune cells. Immune cell function, differentiation, and proliferation are affected in an iron-replete or iron-deficient environment. Adopted from ref. [305], copyright 2022, Frontiers Media S.A. (c) Schematic representation of potential mechanisms by which iron deficiency mediates differentiation of osteoblasts and osteoclasts to produce bone loss. Iron deficiency stimulates osteoclast differentiation and inhibits osteoblast differentiation by upregulating hypoxia-inducible factor $1/2\alpha$ (HIF-$1/2\alpha$) through hypoxia. Adopted from ref. [303], copyright 2023, MDPI (Basel, Switzerland).

Fig. 13. Properties of cobalt ion. (a) Schematic diagram of the hematologic, cardiovascular, immunologic, and genotoxic toxicity of cobalt nanoparticles through direct or dissolution-mediated mechanisms in humans. Adopted from ref. [326], copyright 2020, De Gruyter. (b) Schematic illustration of bioactive cobalt ions mediating macrophage differentiation at various concentrations. Low doses of cobalt ions can induce the formation of M1 or M2 subtypes, high doses can induce the differentiation of M1 subtypes, and extremely high doses can cause the death of macrophages. Adopted from ref. [316] with modification, copyright 2021, Springer Nature. (c) Diagram illustrating the dose range of cobalt as an important balance factor in the application of cobalt-related materials. The relationship between osteogenesis and osteoclast system, immune response, and angiogenesis is better balanced at the dose of 1 ppm cobalt, while low or excessive cobalt can cause the activation of inflammation-related signal pathways during the bone regeneration process, which leads to adverse effects. Adopted from ref. [322], copyright 2019, Ivyspring International Publisher.

4.3.3.3. osteogenic effects of cobalt. Cobalt-based alloys and biomaterials have been proven to facilitate angiogenesis and the bone healing process. By exploiting the hypoxia-like reaction of cobalt ions, a cobalt-doped borosilicate glass scaffold was developed for bone regeneration and angiogenesis. This Co-doped system controlled the release of Co ions and exhibited significant osteogenic abilities on the 3 wt% Co bioactive glass scaffold [320]. TCP scaffolds were prepared and doped with different percentages of cobalt for the investigation of the dosage effect of cobalt on osteogenesis [321]. Among these groups, 2% and 5% Co-TCP demonstrated significant osteogenic and angiogenic effects compared to the TCP group. However, a smaller bone volume and higher vascularization rate were observed in the 5% Co-TCP than in the 2% Co-TCP, indicating that appropriate Co ions positively influenced osteogenesis within a suitable range of vascularization, while excessive Co ions suppressed bone formation. Fig. 13c demonstrated that the appropriate doses of cobalt could promote local bone regeneration, while either low or high concentrations of cobalt inhibited the proliferation of MSCs, thus delaying bone regeneration. At a concentration of 1 ppm, cobalt produces anti-inflammatory, bone regenerative, and angiogenic effects and promotes osteogenesis [322]. Cobalt stabilized hypoxia-inducible factors (HIFs) enhance angiogenesis at the implant site by producing a hypoxic environment, where activates angiogenic factors VEGF, glucose transporter-1, and erythropoietin [323,324]. Cobalt has been used in bone implant materials and alloys for a long time. Although some studies have confirmed the osteoprotective effect and compatibility of cobalt materials, long-term studies have shown that excessive exposure to cobalt brings systemic health hazards, including the nervous system, cardiovascular system, and endocrine system [325].

4.3.4. Copper

4.3.4.1. physicochemical and physiological properties of copper. Copper's ductile, malleable properties, high electrical conductivity (59.6106 S/m), and thermal conductivity (401 W/(mK)) have led to its extensive application in alloy manufacturing. Copper has an atomic number of 29 in group 11 of the periodic table [327]. Copper's oxidation state is weakly basic. Although copper can form a range of valence states from -2 to $+4$, it generally forms $+1$ or $+2$ to maintain ion stability. Due to the interconversion of Cu^+ (cuprous) and Cu^{2+} (cupric), the biological function of Cu ions is to conduct electrons involved in electron transport and synthesize copper-associated proteins in biological processes [328,329]. Copper is an essential element in biological systems as a cofactor in approximately 30 different enzymes. These enzymes rely on copper for their proper functioning and catalytic activity. This is especially important in cellular redox reactions. However, the redox reaction ability of copper and its ability for protein coordination not only participate in cell metabolism but can also produce toxicity under certain amounts [330]. During absorption in the gastrointestinal tract, copper is primarily bound to ceruloplasmin (CP) in hepatocytes. CP then is secreted into the blood and is involved mainly in iron metabolism, promoting the release of iron from certain tissues (Fig. 14a) [331].

4.3.4.2. immunoregulation of copper. Copper deficiency has been shown to lead to reduced levels of IL-2, a phenomenon that may underpin the observed reduction in T cell proliferation. Under conditions of marginal copper deficiency, both T cell proliferative responses and interleukin levels are reduced. Simultaneously, neutrophils show not only a reduction in number but also a diminished capacity to produce superoxide anions and kill microorganisms during significant copper deficiency [332]. In the immune defense process, copper ions can catalyze superoxide anion radicals to produce ROS [333]. Evidence suggests that copper deficiency disrupts immune functions. Not only does copper deficiency cause neurological dysfunction, but it also induces abnormalities in the circulatory system, most commonly neutropenia and anemia [334]. Several studies have shown that a low-copper diet impairs humoral immunity and increases susceptibility to infectious diseases in

animals [334–336]. These lines of evidence all point to functional defects in neutrophils and macrophages as a result of a low-copper diet or environment. Fig. 14b illustrates the potential mechanism by which macrophages are regulated by copper to act for pathogen clearance [337]. Similar to cobalt, the dosage of Cu ions impacts the macrophages' polarization. When stimulated by LPS, M2 macrophages induced by a low dose of Cu ions can be altered into the M1 type, leading to pro-inflammatory effects (Fig. 14d) [316].

4.3.4.3. osteogenic effects of copper. The synthesis and metabolism of bone require the participation of copper, since lysyl oxidase, the copper-dependent enzyme, is involved in the final step of collagen synthesis. This enzyme is copper-dependent, so copper deficiency affects bone development and repair [338,339]. A Cu-containing bioactive glass ceramic (Cu-BGC) was prepared for healing cartilage lesions and reducing local inflammation. The release of Cu^{2+} promoted the chondrocytes' maturation while elevating the differentiation of the anti-inflammatory phenotype of macrophages [340]. Copper ions also reinforce angiogenesis via stabilizing HIF-1α, as well as increasing VEGF production (Fig. 14c) [341–343]. Copper ions also exhibit antibacterial properties in bone regeneration applications [344]. These biological functions of copper facilitate the development and application of novel biomaterials [345,346]. One study fabricated an implant surface using self-assembled copper nanoparticles (CuS NP) and reduced graphene oxide (rGO) to synergize the photocatalytic antibacterial and osteogenic potentials [347]. This material not only combined photothermal therapy (PTT) to enhance the photothermal effect for eliminating bacteria, but also avoided the inactivation of biological agents caused by this effect. Simultaneously, the material, coupled with copper ions and rGO, promotes the integration of vascularized bone, showing promising bone repair and antibacterial properties. M. Shi et al. produced a Cu-incorporated TCP scaffold providing a specific concentration of Cu ions in the microenvironment, thus modulating angiogenesis and providing favorable conditions for bone repair [348]. In another study, Cu ions were combined with l-arginine to explore its osteogenic and antibacterial activity [349]. The incorporation of arginine could attenuate the copper's inhibitory effect upon MSCs' osteogenic development at 100 μM, and the synergistic effect of Cu ions and l-arginine showed stronger antibacterial activity. To combat potential bacterial contamination of stainless-steel implants, researchers incorporated bioactive glass containing copper into the implant coating. This coating exhibited antibacterial and pro-angiogenic properties while maintaining the cytocompatibility and mechanical properties of stainless steel [350].

4.3.5. Zinc

4.3.5.1. physicochemical and physiological properties of zinc. Zinc is a lustrous, diamagnetic metal with the atomic number 30 [151]. It has a hexagonal crystal structure, with each atom in its plane having six neighbors at 265.9 pm, while others are at 290.6 pm [151]. Zinc has comparatively low melting and boiling temperatures (419.5 °C and 907.7 °C, respectively) [354]. Zinc is distributed in multiple organs and tissues within the human body, but is stored in bone and skeletal muscle primarily (Fig. 15b). It is an essential ligand involved in signaling pathways regulating the metabolism of macromolecules as well as gene expression [355]. However, excessive zinc consumption may be detrimental to health, resulting in inhibition of copper and iron absorption, tissue damage, and cell death [356]. Zinc ions are involved in the modification of channel proteins, including MTs, ZnTs, and ZIP family channel proteins. These zinc-related proteins are involved in mediating signal transduction, protein modification, and gene regulation. Their imbalance affects a variety of cells and organs, potentially causing diseases (Fig. 15a) [357].

4.3.5.2. immunoregulation of zinc. Zinc participates in diverse signaling pathways of immune cells [358]. Zinc ions regulated the transcription

Fig. 14. Properties of copper ion. (a) Schematic of the interaction and metabolic mechanism of copper and iron as two trace elements in metabolism. Copper is synthesized by hepatocytes into ceruloplasmin, which regulates iron metabolism. Adopted from ref. [351], copyright 2018, John Wiley and Sons. (b) Illustration of copper facilitating the antimicrobial responses of macrophages. Several supposed mechanisms are given and shown in the figure: direct toxic molecules generated by the Fenton reaction; vesicular accumulation contributing to oxidative stress, or promoting the FPN1-dependent iron export and thus leading to depletion of iron within intracellular bacteria. Adopted from ref. [352], copyright 2013, Portland Press. (c) Schematic diagram of how copper promotes angiogenesis. Copper maintains the hydroxylation of prolyl residues by inhibiting HIF-1α degradation and maintains the concentration of HIF-1α to augment angiogenesis. The figure also depicts the authors' hypothesis that copper directly activates HIF-1α by down-regulating GSK-3β expression. Adopted from ref. [353], copyright 2022, Elsevier. (d) Schematic diagram of bioactive Cu^{2+} inducing differentiation of macrophages and LPS-induced further conversion of M2 subtype into M1 subtype. Adopted from ref. [316] with modification, copyright 2021, Springer Nature.

of AP1, NF-κB, and IRF3 pathways by mediating the downstream signaling molecules of TNF receptor and TLRs in monocytes/macrophages to regulate macrophage metabolism and their effector functions (Fig. 15c) [358]. Zinc also exerts a regulatory role involved in some major signaling pathways of T cells, including those mediated by the TCR, IL-1 receptor (IL-1R), IL-2R, and IL-6R with downstream molecules affected (Fig. 15d) [358]. Since Zn^{2+} deficiency decreases the differentia-

tion, proliferation, and subsistence of numerous types of immune cells–monocytes, PMN leukocytes, NK cells, T cells, and B cells [359], Zn ions must be carefully monitored by signaling transduction and stored effectively [360,361]. Zn^{2+} signals were involved in the activation of TLR-4 by LPS in monocytes [362]. The stimulation by LPS raised the intracellular concentration of dissociative zinc ions, which activated the downstream signaling pathways (MAPKs, NF-κB), and enhanced pro-

Fig. 15. Properties of zinc ion. (a) Diagram of Zn^{2+} involved in protein modification regulated by MTs, ZnTs, and ZIPs family channel proteins, thus participating in signal transduction and gene regulation under various circumstances. Adopted from ref. [357], copyright 2015, Korean J Physiol Pharmacol. (b) Schematic diagram of the proportion of free zinc in serum transported to organs or tissues of the body and the metabolic pathway of zinc ions (including the metabolism of kidney, pancreas, and skin) after absorption of zinc ions through the gastrointestinal tract into the blood. Adopted from ref. [378], copyright 2015, The American Physiological Society. (c) Schematic diagram of zinc cooperated within the signal transduction of monocytes/macrophages with receptors shown on the cell membrane. Adopted from ref. [358], copyright 2021, Elsevier. (d) Schematic diagram of zinc cooperated in some major signaling pathways of T cells, including pathways of TCR, IL-1R, IL-2R, and IL-6R. Receptors and proteins involved in these pathways are shown. Adopted from ref. [358], copyright 2021, Elsevier.

inflammatory cytokines' production [363]. Neutrophils might be attracted by membrane-induced damage in a model of zinc deficiency. Chelation of free Zn^{2+} by using zinc ion chelators has been shown to inhibit chemotaxis, oxidative burst, phagocytosis, and cytokine production in human neutrophils [364]. Zinc signals are related to the activation, degranulation, and generation of cytokines in mast cells [365]. The ZnT5 transporters were abundantly expressed on mast cells, which resulted in FcRI-mediated NF-κB pathway activation and the PKC translocation of mast cells, hence mediating cytokines' production in delayed-type allergic responses [366,367]. Zn^{2+} influences the adaptive immune

response depending on peculiar cell types. It shows that zinc depletion switched the Th1/Th2 proportion into a Th1-dominant type and inhibited the activation of Th17 cells, therefore impairing the normal function of the whole T lymphocyte subsets [368]. Lower Zn^{2+} intake decreased the IL-12 synthesis by monocytes/macrophages, resulting in impaired Th1 differentiation [369]. B cells are indirectly affected by Zn ions, since BCRs are connected to the ZIP10 transporter in signal transduction, and a ZIP10 deficit lowered B-cell generation and proliferation [370].

4.3.5.3. osteogenic effects of zinc. Most of the zinc element is stored in the bone matrix. It is involved in stabilizing the bone structure and regulating the synthesis of protein cofactors [371]. Novel zinc scaffolds have been verified in both osteogenic and angiogenic processes. Zinc alloys are applied significantly in bone implant materials since their mechanical characteristics are comparable to mammalian bone tissues, and zinc is involved in several signal pathways that influence the functioning and proliferation of osteogenic cells [372–374]. Several biomaterials incorporating Zn have been proposed. Zn ions promoted osteoblastogenesis through TGF-β/Smad signal pathways in osteoblastic cells [375]. Zn deposited on HA coating also exhibited antibacterial and osteogenesis effects [376]. A zinc scaffold demonstrates the ability to activate the P38 pathway within monocytes, leading to BMSCs' recruitment to the site of bone defect. Furthermore, after implantation, there is an observed increase in the angiogenesis-related gene expression, indicating enhanced angiogenesis in the bone regeneration process [377].

5. Conclusion

Research has shown that the immune microenvironment induced by biometal ions is important for bone tissue regeneration. These inorganic bioactive factors are cost-effective, stable, and can be easily incorporated into bioinert matrices, expanding their practical applications in bone repair. This article provided a comprehensive overview of the interaction between biometal ions, immune cells, and the skeletal system.

Although the role of metal ions in osteoimmunomodulation has been uncovered, the underlying mechanisms are not yet clear. Previous studies have mainly focused on the polarization of macrophages and metal ions released from biomaterials, given the impacts of macrophages on the inflammatory response processes during biomaterial integration. However, other cells involved in the immune response, such as natural killer cells, mononuclear phagocytes, and lymphocytes, and their impacts on biomaterial-induced bone tissue repair are also worth further investigation.

Existing research on metal ions has demonstrated various combinations. In many cases, two or more bioactive ions are introduced into materials to synergistically promote bone tissue regeneration by harnessing their unique osteo-immunomodulatory properties. While the combination of multiple ions has shown stronger reparative effects compared to the use of a single ion, comprehensive studies elucidating the underlying mechanisms of collective regulatory effects of multiple metal ions in this context are necessary.

Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

CRediT authorship contribution statement

Shubo Liu: Writing – original draft, Visualization. **Zhengjie Lin:** Writing – original draft, Funding acquisition. **Wei Qiao:** Conceptualization, Writing – review & editing, Funding acquisition. **Bin Chen:** Writing – review & editing, Supervision, Funding acquisition. **Jie Shen:** Conceptualization, Writing – review & editing, Supervision, Resources, Funding acquisition.

References

[1] Z.J. Balogh, M.K. Reumann, R.L. Gruen, P. Mayer-Kuckuk, M.A. Schuetz, I.A. Harris, B.J. Gabbe, M. Bhandari, Advances and future directions for management of trauma patients with musculoskeletal injuries, The Lancet 380 (9847) (2012) 1109–1119.

[2] Global, regional, and national burden of bone fractures in 204 countries and territories 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019, Lancet Healthy Longev 2 (9) (2021) e580–e592.

[3] D. Leilei, Y. Pengpeng, J.A. Haagsma, J. Ye, W. Yuan, E. Yuliang, D. Xiao, G. Xin, J. Cuirong, W. Linhong, M.S. Bannick, W.C. Mountjoy-Venning, C.N. Hawley, Z. Liu, M. Smith, S.L. James, T. Vos, C.J.L. Murray, The burden of injury in China, 1990-2017: findings from the Global Burden of Disease Study 2017, The Lancet. Public health 4 (9) (2019) e449–e461.

[4] Z. Zhu, T. Zhang, Y. Shen, P.-F. Shan, The burden of fracture in China from 1990 to 2019, Archives of Osteoporosis 19 (1) (2023) 1.

[5] B. Wildemann, A. Ignatius, F. Leung, L.A. Taitsman, R.M. Smith, R. Pesántez, M.J. Stoddart, R.G. Richards, J.B. Jupiter, Non-union bone fractures, Nat Rev Dis Primers 7 (1) (2021) 57.

[6] T.F. Moriarty, W.J. Metsemakers, M. Morgenstern, M.I. Hofstee, A. Vallejo Diaz, J.E. Cassat, B. Wildemann, M. Depypere, E.M. Schwarz, R.G. Richards, Fracture-related infection, Nat Rev Dis Primers 8 (1) (2022) 67.

[7] M. Vallet-Regi, E. Ruiz-Hernandez, Bioceramics: from bone regeneration to cancer nanomedicine, Adv Mater 23 (44) (2011) 5177–5218.

[8] J. Zhou, Z. Zhang, J. Joseph, X. Zhang, B.E. Ferdows, D.N. Patel, W. Chen, G. Banfi, R. Molinaro, D. Cosco, Biomaterials and nanomedicine for bone regeneration: Progress and future prospects, Exploration, Wiley Online Library, 2021.

[9] W. Qiao, H. Xie, J. Fang, J. Shen, W. Li, D. Shen, J. Wu, S. Wu, X. Liu, Y. Zheng, Sequential activation of heterogeneous macrophage phenotypes is essential for biomaterials-induced bone regeneration, Biomaterials 276 (2021) 121038.

[10] T. Sibai, E.F. Morgan, T.A. Einhorn, Anabolic agents and bone quality, Clinical Orthopaedics and Related Research® 469 (8) (2011) 2215–2224.

[11] L. Claes, S. Recknagel, A. Ignatius, Fracture healing under healthy and inflammatory conditions, Nature Reviews Rheumatology 8 (3) (2012) 133–143.

[12] E. Tsiridis, N. Upadhyay, P. Giannoudis, Molecular aspects of fracture healing: which are the important molecules? Injury 38 (1) (2007) S11–S25.

[13] X.L. Griffin, N. Parsons, M.L. Costa, D. Metcalfe, Ultrasound and shockwave therapy for acute fractures in adults, Cochrane Database of Systematic Reviews (6) (2014).

[14] M. Jagodzinski, C. Krettek, Effect of mechanical stability on fracture healing–an update, Injury 38 (Suppl 1) (2007) S3-10.

[15] L. Xiao, Y. Ma, R. Crawford, J. Mendhi, Y. Zhang, H. Lu, Q. Zhao, J. Cao, C. Wu, X. Wang, The interplay between hemostasis and immune response in biomaterial development for osteogenesis, Materials Today 54 (2022) 202–224.

[16] J. Pajarinen, T. Lin, E. Gibon, Y. Kohno, M. Maruyama, K. Nathan, L. Lu, Z. Yao, S.B. Goodman, Mesenchymal stem cell-macrophage crosstalk and bone healing, Biomaterials 196 (2019) 80–89.

[17] M. Tsukasaki, H. Takayanagi, Osteoimmunology: evolving concepts in bone–immune interactions in health and disease, Nature Reviews Immunology 19 (10) (2019) 626–642.

[18] D.A. Flevas, M.G. Papageorgiou, P. Drakopoulos, I.K. Triantafyllopoulos, G.I. Lambrou, Osteoimmunology of Fracture Healing: A Brief Review on the Immune System's Cellular Milieu Role in Bone Injury, Acta Orthopaedica Et Traumatologica Hellenica 72 (4) (2021).

[19] H. Newman, Y.V. Shih, S. Varghese, Resolution of inflammation in bone regeneration: From understandings to therapeutic applications, Biomaterials 277 (2021) 121114.

[20] G. Zhu, T. Zhang, M. Chen, K. Yao, X. Huang, B. Zhang, Y. Li, J. Liu, Y. Wang, Z. Zhao, Bone physiological microenvironment and healing mechanism: Basis for future bone-tissue engineering scaffolds, Bioactive materials 6 (11) (2021) 4110–4140.

[21] R. Hänsch, R.R. Mendel, Physiological functions of mineral micronutrients (cu, Zn, Mn, Fe, Ni, Mo, B, cl), Current opinion in plant biology 12 (3) (2009) 259–266.

[22] R.R. Mendel, A.G. Smith, A. Marquet, M.J. Warren, Metal and cofactor insertion, Natural product reports 24 (5) (2007) 963–971.

[23] W. Wang, L.P. Billen, Y. Li, Sequence diversity, metal specificity, and catalytic proficiency of metal-dependent phosphorylating DNA enzymes, Chemistry & biology 9 (4) (2002) 507–517.

[24] W. Wang, K.W.K. Yeung, Bone grafts and biomaterials substitutes for bone defect repair: A review, Bioact Mater 2 (4) (2017) 224–247.

[25] C. Wang, R. Zhang, X. Wei, M. Lv, Z. Jiang, Metalloimmunology: The metal ion–controlled immunity, Advances in immunology 145 (2020) 187–241.

[26] K. Placek, J.L. Schultze, A.C. Aschenbrenner, Epigenetic reprogramming of immune cells in injury, repair, and resolution, The Journal of Clinical Investigation 129 (8) (2019) 2994–3005.

[27] R. Whitaker, B. Hernaez-Estrada, R.M. Hernandez, E. Santos-Vizcaino, K.L. Spiller, Immunomodulatory Biomaterials for Tissue Repair, Chemical Reviews 121 (18) (2021) 11305–11335.

[28] J. Parkin, B. Cohen, An overview of the immune system, Lancet 357 (9270) (2001) 1777–1789.

[29] P.J. Delves, I.M. Roitt, The immune system. First of two parts, N Engl J Med 343 (1) (2000) 37–49.

[30] L. Sun, X. Wang, J. Saredy, Z. Yuan, X. Yang, H. Wang, Innate-adaptive immunity interplay and redox regulation in immune response, Redox Biol 37 (2020) 101759.

[31] C.A. Thaiss, N. Zmora, M. Levy, E. Elinav, The microbiome and innate immunity, Nature 535 (7610) (2016) 65–74.

[32] F.A. Bonilla, H.C. Oettgen, Adaptive immunity, J Allergy Clin Immunol 125 (Suppl 2) (2010) S33–S40 2.

[33] L. Palmer, C. Briggs, S. McFadden, G. Zini, J. Burthem, G. Rozenberg, M. Proytcheva, S.J. Machin, ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features, Int J Lab Hematol 37 (3) (2015) 287–303.

[34] L. Ziegler-Heitbrock, P. Ancuta, S. Crowe, M. Dalod, V. Grau, D.N. Hart, P.J. Leenen, Y.J. Liu, G. MacPherson, G.J. Randolph, J. Scherberich, J. Schmitz, K. Shortman, S. Sozzani, H. Strobl, M. Zembala, J.M. Austyn, M.B. Lutz, Nomenclature of monocytes and dendritic cells in blood, Blood 116 (16) (2010) e74–e80.

[35] P.J. Delves, I.M. Roitt, The immune system, New England journal of medicine 343 (1) (2000) 37–49.

[36] T.M.J. Evers, V. Sheikhhassani, M.C. Haks, C. Storm, T.H.M. Ottenhoff, A. Mashaghi, Single-cell analysis reveals chemokine-mediated differential regulation of monocyte mechanics, iScience 25 (1) (2022) 103555.

[37] H. Kumar, T. Kawai, S. Akira, Pathogen recognition by the innate immune system, Int Rev Immunol 30 (1) (2011) 16–34.

[38] D.A. Ovchinnikov, Macrophages in the embryo and beyond: much more than just giant phagocytes, Genesis 46 (9) (2008) 447–462.

[39] L. Franken, M. Schiwon, C. Kurts, Macrophages: sentinels and regulators of the immune system, Cellular microbiology 18 (4) (2016) 475–487.

[40] E. Meylan, J. Tschopp, M. Karin, Intracellular pattern recognition receptors in the host response, Nature 442 (7098) (2006) 39–44.

[41] M. Nahrendorf, F.F. Hoyer, A.E. Meerwaldt, M.M.T. van Leent, M.L. Senders, C. Calcagno, P.M. Robson, G. Soultanidis, C. Pérez-Medina, A.J.P. Teunissen, Y.C. Toner, K. Ishikawa, K. Fish, K. Sakurai, E.M. van Leeuwen, E.D. Klein, A.M. Sofias, T. Reiner, D. Rohde, A.D. Aguirre, G. Wojtkiewicz, S. Schmidt, Y. Iwamoto, D. Izquierdo-Garcia, P. Caravan, F.K. Swirski, R. Weissleder, W.J.M. Mulder, Imaging Cardiovascular and Lung Macrophages With the Positron Emission Tomography Sensor (64)Cu-Macrin in Mice, Rabbits, and Pigs, Circ Cardiovasc Imaging 13 (10) (2020) e010586.

[42] L.C. Davies, S.J. Jenkins, J.E. Allen, P.R. Taylor, Tissue-resident macrophages, Nature immunology 14 (10) (2013) 986–995.

[43] M. Kohyama, W. Ise, B.T. Edelson, P.R. Wilker, K. Hildner, C. Mejia, W.A. Frazier, T.L. Murphy, K.M. Murphy, Role for Spi-C in the development of red pulp macrophages and splenic iron homeostasis, Nature 457 (7227) (2009) 318–321.

[44] S.B. Goodman, E. Gibon, J. Gallo, M. Takagi, Macrophage Polarization and the Osteoimmunology of Periprosthetic Osteolysis, Current Osteoporosis Reports (2022) 1–10.

[45] P.J. Murray, T.A. Wynn, Protective and pathogenic functions of macrophage subsets, Nat Rev Immunol 11 (11) (2011) 723–737.

[46] F.O. Martinez, A. Sica, A. Mantovani, M. Locati, Macrophage activation and polarization, Frontiers in Bioscience-Landmark 13 (2) (2008) 453–461.

[47] S. Gordon, F.O. Martinez, Alternative activation of macrophages: mechanism and functions, Immunity 32 (5) (2010) 593–604.

[48] L.X. Wang, S.X. Zhang, H.J. Wu, X.L. Rong, J. Guo, M2b macrophage polarization and its roles in diseases, J Leukoc Biol 106 (2) (2019) 345–358.

[49] A. Shapouri-Moghaddam, S. Mohammadian, H. Vazini, M. Taghadosi, S.A. Esmaeili, F. Mardani, A. Seifi, A. Mohammadi, J.T. Afshari, A. Sahebkar, Macrophage plasticity, polarization, and function in health and disease, J Cell Physiol 233 (9) (2018) 6425–6440.

[50] P. Di Benedetto, P. Ruscitti, Z. Vadasz, E. Toubi, R. Giacomelli, Macrophages with regulatory functions, a possible new therapeutic perspective in autoimmune diseases, Autoimmun Rev 18 (10) (2019) 102369.

[51] F.O. Martinez, Regulators of macrophage activation, European journal of immunology 41 (6) (2011) 1531–1534.

[52] C.S. Bahney, R.L. Zondervan, P. Allison, A. Theologis, J.W. Ashley, J. Ahn, T. Miclau, R.S. Marcucio, K.D. Hankenson, Cellular biology of fracture healing, J Orthop Res 37 (1) (2019) 35–50.

[53] Y. Shen, B. Zhang, X. Wei, X. Guan, W. Zhang, CXCL8 is a prognostic biomarker and correlated with TNBC brain metastasis and immune infiltration, Int Immunopharmacol 103 (2022) 108454.

[54] T. Germann, E. Rüde, Interleukin-12, Int Arch Allergy Immunol 108 (2) (1995) 103–112.

[55] M.J. Pittet, M. Nahrendorf, F.K. Swirski, The journey from stem cell to macrophage, Ann N Y Acad Sci 1319 (1) (2014) 1–18.

[56] J. Banchereau, F. Briere, C. Caux, J. Davoust, S. Lebecque, Y.-J. Liu, B. Pulendran, K. Palucka, Immunobiology of dendritic cells, Annual review of immunology 18 (1) (2000) 767–811.

[57] J. Banchereau, R.M. Steinman, Dendritic cells and the control of immunity, Nature 392 (6673) (1998) 245–252.

[58] C.D. Surh, J. Sprent, Homeostasis of naive and memory T cells, Immunity 29 (6) (2008) 848–862.

[59] L. Yam, C.Y. Li, W. Crosby, Cytochemical identification of monocytes and granulocytes, American Journal of Clinical Pathology 55 (3) (1971) 283–290.

[60] T.N. Mayadas, X. Cullere, C.A. Lowell, The multifaceted functions of neutrophils, Annual review of pathology 9 (2014) 181.

[61] W.M. Nauseef, N. Borregaard, Neutrophils at work, Nature immunology 15 (7) (2014) 602–611.

[62] A. Rigoni, M. Colombo, C. Pucillo, Mast cells, basophils and eosinophils: From allergy to cancer, Seminars in immunology (2018) 29–34.

[63] J.-P. Kinet, The high-affinity IgE receptor (FcεRI): from physiology to pathology, Annual review of immunology 17 (1) (1999) 931–972.

[64] K.D. Stone, C. Prussin, D.D. Metcalfe, IgE, mast cells, basophils, and eosinophils, Journal of Allergy and Clinical Immunology 125 (2) (2010) S73–S80.

[65] M.J. Hickey, P. Kubes, Intravascular immunity: the host-pathogen encounter in blood vessels, Nat Rev Immunol 9 (5) (2009) 364–375.

[66] J.A. Hamerman, K. Ogasawara, L.L. Lanier, NK cells in innate immunity, 17(1) (2005) 29-35.

[67] A. Pfefferle, B. Jacobs, A. Haroun-Izquierdo, L. Kveberg, E. Sohlberg, K.J. Malmberg, Deciphering Natural Killer Cell Homeostasis, Front Immunol 11 (2020) 812.

[68] M.J. Smyth, Y. Hayakawa, K. Takeda, H. Yagita, New aspects of natural-killer-cell surveillance and therapy of cancer, Nat Rev Cancer 2 (11) (2002) 850–861.

[69] A. Poli, T. Michel, M. Thérésine, E. Andrès, F. Hentges, J. Zimmer, CD56bright natural killer (NK) cells: an important NK cell subset, Immunology 126 (4) (2009) 458–465.

[70] M.A. Cooper, T.A. Fehniger, M.A. Caligiuri, The biology of human natural killer-cell subsets, Trends Immunol 22 (11) (2001) 633–640.

[71] A. Jarry, N. Cerf-bensussan, N. Brousse, F. Selz, D. Guy-grand, Subsets of CD3+ (T cell receptor α/β or γ/δ) and CD3− lymphocytes isolated from normal human gut epithelium display phenotypical features different from their counterparts in peripheral blood, European journal of immunology 20 (5) (1990) 1097–1103.

[72] H. von Boehmer, Positive selection of lymphocytes, Cell 76 (2) (1994) 219–228.

[73] N.J. MacIver, R.D. Michalek, J.C. Rathmell, Metabolic regulation of T lymphocytes, Annual review of immunology 31 (2013) 259.

[74] T.K. Starr, S.C. Jameson, K.A. Hogquist, Positive and negative selection of T cells, Annual review of immunology 21 (1) (2003) 139–176.

[75] J. Sprent, H. Kishimoto, The thymus and negative selection, Immunological reviews 185 (1) (2002) 126–135.

[76] F. Sallusto, J. Geginat, A. Lanzavecchia, Central memory and effector memory T cell subsets: function, generation, and maintenance, Annual review of immunology 22 (2004) 745.

[77] E.L. Reinherz, S.F. Schlossman, The differentiation and function of human T lymphocytes, (1980).

[78] J. Saravia, N.M. Chapman, H. Chi, Helper T cell differentiation, Cellular & molecular immunology 16 (7) (2019) 634–643.

[79] R.V. Luckheeram, R. Zhou, A.D. Verma, B. Xia, CD4+ T cells: differentiation and functions, Clinical and developmental immunology (2012) 2012.

[80] S. Romagnani, Th1/th2 cells, Inflammatory bowel diseases 5 (4) (1999) 285–294.

[81] T. Mosmann, R. Coffman, TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties, Annual review of immunology 7 (1) (1989) 145–173.

[82] S. Romagnani, T-cell subsets (Th1 versus Th2), Annals of allergy, asthma & immunology 85 (1) (2000) 9–21.

[83] V. Singh, S. Mehrotra, S. Agarwal, The paradigm of Th1 and Th2 cytokines, Immunologic research 20 (3) (1999) 147–161.

[84] S. Crotty, Follicular helper CD4 T cells (Tfh), Annual review of immunology 29 (1) (2011) 621–663.

[85] G.S. Baht, L. Vi, B.A. Alman, The role of the immune cells in fracture healing, Current osteoporosis reports 16 (2) (2018) 138–145.

[86] L.A. Tesmer, S.K. Lundy, S. Sarkar, D.A. Fox, Th17 cells in human disease, Immunological reviews 223 (1) (2008) 87–113.

[87] S. Sakaguchi, T. Yamaguchi, T. Nomura, M. Ono, Regulatory T cells and immune tolerance, cell 133 (5) (2008) 775–787.

[88] W. Wang, N. Sung, A. Gilman-Sachs, J. Kwak-Kim, T helper, Th) cell profiles in pregnancy and recurrent pregnancy losses: Th1/Th2/Th9/Th17/Th22/Tfh cells, Frontiers in immunology 11 (2020) 2025.

[89] L. Jia, C. Wu, The biology and functions of Th22 cells, T helper cell differentiation and their function (2014) 209–230.

[90] M.H. Andersen, D. Schrama, P. thor Straten, J.C. Becker, Cytotoxic T cells, Journal of Investigative Dermatology 126 (1) (2006) 32–41.

[91] M.A. Cox, S.M. Kahan, A.J. Zajac, Anti-viral CD8 T cells and the cytokines that they love, Virology 435 (1) (2013) 157–169.

[92] C. Mauri, A. Bosma, Immune regulatory function of B cells, Annual review of immunology 30 (2012) 221–241.

[93] S.P. Schoenberger, R.E. Toes, E.I. Van Der Voort, R. Offringa, C.J. Melief, T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions, Nature 393 (6684) (1998) 480–483.

[94] T.W. LeBien, T.F. Tedder, B lymphocytes: how they develop and function, The Journal of the American Society of Hematology 112 (5) (2008) 1570–1580.

[95] T.A. Packard, J.C. Cambier, B lymphocyte antigen receptor signaling: initiation, amplification, and regulation, F1000prime reports 5 (2013).

[96] M.C. Raff, M. Megson, J.J. Owen, M.D. COOPER, Early production of intracellular IgM by B-lymphocyte precursors in mouse, Nature 259 (5540) (1976) 224–226.

[97] M. Boes, Role of natural and immune IgM antibodies in immune responses, Molecular immunology 37 (18) (2000) 1141–1149.

[98] G. Vidarsson, G. Dekkers, T. Rispens, IgG subclasses and allotypes: from structure to effector functions, Frontiers in immunology 5 (2014) 520.

[99] J.M. Woof, M.A. Kerr, IgA function–variations on a theme, Immunology 113 (2) (2004) 175.

[100] J.R. Birch, A.J. Racher, Antibody production, Advanced drug delivery reviews 58 (5-6) (2006) 671–685.

[101] S.J. Galli, M. Tsai, IgE and mast cells in allergic disease, Nature medicine 18 (5) (2012) 693–704.

[102] M.I. Vazquez, J. Catalan-Dibene, A. Zlotnik, B cells responses and cytokine production are regulated by their immune microenvironment, Cytokine 74 (2) (2015) 318–326.

[103] T.L. Anderson, Fracture mechanics: fundamentals and applications, CRC press, 2017.

[104] M. Rupp, N. Walter, C. Pfeifer, S. Lang, M. Kerschbaum, W. Krutsch, F. Baumann, V. Alt, The Incidence of Fractures Among the Adult Population of Germany–an Analysis From 2009 through 2019, Dtsch Arztebl Int 118 (40) (2021) 665–669.

[105] A. Schindeler, M.M. McDonald, P. Bokko, D.G. Little, Bone remodeling during fracture repair: The cellular picture, Semin Cell Dev Biol 19 (5) (2008) 459–466.

[106] J.G. Tidball, Regulation of muscle growth and regeneration by the immune system, Nature Reviews Immunology 17 (3) (2017) 165–178.

[107] B.A. Zelle, F.H. Fu, Pathogenesis of soft tissue and bone repair, Rehabilitation for the Postsurgical Orthopedic Patient: Third Edition, Elsevier Inc, 2013, pp. 2–14.

[108] T.A. Järvinen, T.L. Järvinen, M. Kääriäinen, H. Kalimo, M. Järvinen, Muscle injuries: biology and treatment, The American journal of sports medicine 33 (5) (2005) 745–764.

[109] L.A. O'Neill, D.G. Hardie, Metabolism of inflammation limited by AMPK and pseudo-starvation, Nature 493 (7432) (2013) 346–355.

[110] S. Leibovich, R. Ross, The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum, The American journal of pathology 78 (1) (1975) 71.

[111] N. Udagawa, N. Takahashi, T. Akatsu, H. Tanaka, T. Sasaki, T. Nishihara, T. Koga, T.J. Martin, T. Suda, Origin of osteoclasts: mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells, Proc Natl Acad Sci U S A 87 (18) (1990) 7260–7264.

[112] M. Alnaeeli, Y.T. Teng, Dendritic cells differentiate into osteoclasts in bone marrow microenvironment in vivo, Blood 113 (1) (2009) 264–265 author reply 265.

[113] A. Ozaki, M. Tsunoda, S. Kinoshita, R. Saura, Role of fracture hematoma and periosteum during fracture healing in rats: interaction of fracture hematoma and the periosteum in the initial step of the healing process, J Orthop Sci 5 (1) (2000) 64–70.

[114] P. Kolar, K. Schmidt-Bleek, H. Schell, T. Gaber, D. Toben, G. Schmidmaier, C. Perka, F. Buttgereit, G.N. Duda, The early fracture hematoma and its potential role in fracture healing, Tissue Eng Part B Rev 16 (4) (2010) 427–434.

[115] M.V. Thomas, D.A. Puleo, Infection, inflammation, and bone regeneration: a paradoxical relationship, J Dent Res 90 (9) (2011) 1052–1061.

[116] A. Pimorady-Esfahani, M.D. Grounds, P.G. McMenamin, Macrophages and dendritic cells in normal and regenerating murine skeletal muscle, Muscle Nerve 20 (2) (1997) 158–166.

[117] H. Schell, G.N. Duda, A. Peters, S. Tsitsilonis, K.A. Johnson, K. Schmidt-Bleek, The haematoma and its role in bone healing, J Exp Orthop 4 (1) (2017) 5.

[118] A. Grützkau, S. Krüger-Krasagakes, H. Baumeister, C. Schwarz, H. Kögel, P. Welker, U. Lippert, B.M. Henz, A. Möller, Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: implications for the biological significance of VEGF206, Mol Biol Cell 9 (4) (1998) 875–884.

[119] R.J. Blair, H. Meng, M.J. Marchese, S. Ren, L.B. Schwartz, M.G. Tonnesen, B.L. Gruber, Human mast cells stimulate vascular tube formation. Tryptase is a novel, potent angiogenic factor, J Clin Invest 99 (11) (1997) 2691–2700.

[120] J. Kroner, A. Kovtun, J. Kemmler, J.J. Messmann, G. Strauss, S. Seitz, T. Schinke, M. Amling, J. Kotrba, J. Froebel, J. Dudeck, A. Dudeck, A. Ignatius, Mast Cells Are Critical Regulators of Bone Fracture-Induced Inflammation and Osteoclast Formation and Activity, J Bone Miner Res 32 (12) (2017) 2431–2444.

[121] L. Zhang, T. Wang, M. Chang, C. Kaiser, J.D. Kim, T. Wu, X. Cao, X. Zhang, E.M. Schwarz, Teriparatide Treatment Improves Bone Defect Healing Via Anabolic Effects on New Bone Formation and Non-Anabolic Effects on Inhibition of Mast Cells in a Murine Cranial Window Model, J Bone Miner Res 32 (9) (2017) 1870–1883.

[122] C.J. Hauser, P. Joshi, Q. Jones, X. Zhou, D.H. Livingston, R.F. Lavery, Suppression of natural killer cell activity in patients with fracture/soft tissue injury, Arch Surg 132 (12) (1997) 1326–1330.

[123] I. Könnecke, A. Serra, T. El Khassawna, C. Schlundt, H. Schell, A. Hauser, A. Ellinghaus, H.D. Volk, A. Radbruch, G.N. Duda, K. Schmidt-Bleek, T and B cells participate in bone repair by infiltrating the fracture callus in a two-wave fashion, Bone 64 (2014) 155–165.

[124] T.A. Einhorn, L.C. Gerstenfeld, Fracture healing: mechanisms and interventions, Nat Rev Rheumatol 11 (1) (2015) 45–54.

[125] G. Sun, Y. Wang, Y. Ti, J. Wang, J. Zhao, H. Qian, Regulatory B cell is critical in bone union process through suppressing proinflammatory cytokines and stimulating Foxp3 in Treg cells, Clin Exp Pharmacol Physiol 44 (4) (2017) 455–462.

[126] K.M. Lee, R.T. Stott, G. Zhao, J. SooHoo, W. Xiong, M.M. Lian, L. Fitzgerald, S. Shi, E. Akrawi, J. Lei, S. Deng, H. Yeh, J.F. Markmann, J.I. Kim, TGF-β-producing regulatory B cells induce regulatory T cells and promote transplantation tolerance, Eur J Immunol 44 (6) (2014) 1728–1736.

[127] R. Dimitriou, E. Tsiridis, P.V. Giannoudis, Current concepts of molecular aspects of bone healing, Injury 36 (12) (2005) 1392–1404.

[128] L.C. Gerstenfeld, D.M. Cullinane, G.L. Barnes, D.T. Graves, T.A. Einhorn, Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation, J Cell Biochem 88 (5) (2003) 873–884.

[129] G.S. Baht, D. Silkstone, L. Vi, P. Nadesan, Y. Amani, H. Whetstone, Q. Wei, B.A. Alman, Erratum: Exposure to a youthful circulation rejuvenates bone repair through modulation of β-catenin, Nat Commun 6 (2015) 7761.

[130] M.K. Chang, L.J. Raggatt, K.A. Alexander, J.S. Kuliwaba, N.L. Fazzalari, K. Schroder, E.R. Maylin, V.M. Ripoll, D.A. Hume, A.R. Pettit, Osteal tissue macrophages are intercalated throughout human and mouse bone lining tissues and regulate osteoblast function in vitro and in vivo, J Immunol 181 (2) (2008) 1232–1244.

[131] D.M. Mosser, J.P. Edwards, Exploring the full spectrum of macrophage activation, Nat Rev Immunol 8 (12) (2008) 958–969.

[132] G. Juban, B. Chazaud, Metabolic regulation of macrophages during tissue repair: insights from skeletal muscle regeneration, FEBS Lett 591 (19) (2017) 3007–3021.

[133] J.W. Godwin, A.R. Pinto, N.A. Rosenthal, Chasing the recipe for a pro-regenerative immune system, Semin Cell Dev Biol 61 (2017) 71–79.

[134] K.J. Lavine, S. Epelman, K. Uchida, K.J. Weber, C.G. Nichols, J.D. Schilling, D.M. Ornitz, G.J. Randolph, D.L. Mann, Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart, Proc Natl Acad Sci U S A 111 (45) (2014) 16029–16034.

[135] A.R. Pettit, M.K. Chang, D.A. Hume, L.J. Raggatt, Osteal macrophages: a new twist on coupling during bone dynamics, Bone 43 (6) (2008) 976–982.

[136] N. Manabe, H. Kawaguchi, H. Chikuda, C. Miyaura, M. Inada, R. Nagai, Y. Nabeshima, K. Nakamura, A.M. Sinclair, R.H. Scheuermann, M. Kuro-o, Connection between B lymphocyte and osteoclast differentiation pathways, J Immunol 167 (5) (2001) 2625–2631.

[137] X. Han, Q. Yang, L. Lin, C. Xu, C. Zheng, X. Chen, Y. Han, M. Li, W. Cao, K. Cao, Q. Chen, G. Xu, Y. Zhang, J. Zhang, R.J. Schneider, Y. Qian, Y. Wang, G. Brewer, Y. Shi, Interleukin-17 enhances immunosuppression by mesenchymal stem cells, Cell Death Differ 21 (11) (2014) 1758–1768.

[138] D. Nam, E. Mau, Y. Wang, D. Wright, D. Silkstone, H. Whetstone, C. Whyne, B. Alman, T-lymphocytes enable osteoblast maturation via IL-17F during the early phase of fracture repair, PLoS One 7 (6) (2012) e40044.

[139] B. McKibbin, The biology of fracture healing in long bones, J Bone Joint Surg Br 60-b (2) (1978) 150–162.

[140] G. Mori, P. D'Amelio, R. Faccio, G. Brunetti, The Interplay between the bone and the immune system, Clin Dev Immunol 2013 (2013) 720504.

[141] P.J. Muire, L.H. Mangum, J.C. Wenke, Time course of immune response and immunomodulation during normal and delayed healing of musculoskeletal wounds, Frontiers in immunology 11 (2020) 1056.

[142] S. Gordon, The macrophage: past, present and future, European journal of immunology 37 (S1) (2007) S9–S17.

[143] K. Okamoto, T. Nakashima, M. Shinohara, T. Negishi-Koga, N. Komatsu, A. Terashima, S. Sawa, T. Nitta, H. Takayanagi, Osteoimmunology: the conceptual framework unifying the immune and skeletal systems, Physiological reviews 97 (4) (2017) 1295–1349.

[144] P. Ten Dijke, J. Fu, P. Schaap, B.A. Roelen, Signal transduction of bone morphogenetic proteins in osteoblast differentiation, JBJS 85 (suppl_3) (2003) 34–38.

[145] H. Huang, H.J. Kim, E.J. Chang, Z.H. Lee, S.J. Hwang, H.M. Kim, Y. Lee, H.H. Kim, IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling, Cell Death Differ 16 (10) (2009) 1332–1343.

[146] H. Taniguchi, Mast cells in fracture healing: an experimental study using rat model, Nihon Seikeigeka Gakkai Zasshi 64 (10) (1990) 949–957.

[147] K. Banovac, F. Banovac, J. Yang, E. Koren, Interaction of osteoblasts with extracellular matrix: effect of mast cell chymase, Proc Soc Exp Biol Med 203 (2) (1993) 221–235.

[148] H. Sychrova, Yeast as a model organism to study transport and homeostasis of alkali metal cations, Physiological research 53 (2004) S91–S98.

[149] E. Gouaux, R. Mackinnon, Principles of selective ion transport in channels and pumps, Science 310 (5753) (2005) 1461–1465.

[150] K. Lodders, Solar system abundances and condensation temperatures of the elements, The Astrophysical Journal 591 (2) (2003) 1220.

[151] N.N. Greenwood, A. Earnshaw, Chemistry of the Elements, Elsevier2012.

[152] C.W. Kamienski, D.P. McDonald, M.W. Stark, J.R. Papcun, Lithium and lithium compounds, Kirk-Othmer Encyclopedia of Chemical Technology (2000).

[153] E. Jakobsson, O. Arguello-Miranda, S.W. Chiu, Z. Fazal, J. Kruczek, S. Nunez-Corrales, S. Pandit, L. Pritchet, Towards a Unified Understanding of Lithium Action in Basic Biology and its Significance for Applied Biology, J Membr Biol 250 (6) (2017) 587–604.

[154] K.J. Liu, Y.L. Lee, Y.Y. Yang, N.Y. Shih, C.C. Ho, Y.C. Wu, T.S. Huang, M.C. Huang, H.C. Liu, W.W. Shen, S.J. Leu, Modulation of the development of human monocyte-derived dendritic cells by lithium chloride, J Cell Physiol 226 (2) (2011) 424–433.

[155] K. Sakrajda, A. Szczepankiewicz, Inflammation-Related Changes in Mood Disorders and the Immunomodulatory Role of Lithium, Int J Mol Sci 22 (4) (2021).

[156] C. Petersein, U. Sack, R. Mergl, J. Schönherr, F.M. Schmidt, N. Lichtblau, K.C. Kirkby, H. Bauer, H. Himmerich, Impact of lithium alone and in combination with antidepressants on cytokine production in vitro, J Neural Transm (Vienna) 122 (1) (2015) 109–122.

[157] M. Kubera, M. Bubak-Satora, V. Holan, W. Krol, A. Basta-Kaim, A. Roman, A. Skowron-Cendrzak, J. Shani, Modulation of cell-mediated immunity by lithium chloride, Z Naturforsch C J Biosci 49 (9-10) (1994) 679–683.

[158] N. Maddu, P.B. Raghavendra, Review of lithium effects on immune cells, Immunopharmacol Immunotoxicol 37 (2) (2015) 111–125.

[159] S.K. Wong, K.Y. Chin, S. Ima-Nirwana, The Skeletal-Protecting Action and Mechanisms of Action for Mood-Stabilizing Drug Lithium Chloride: Current Evidence and Future Potential Research Areas, Front Pharmacol 11 (2020) 430.

[160] E. Bettini, E. Magnani, G.C. Terstappen, Lithium induces gene expression through lymphoid enhancer-binding factor/T-cell factor responsive element in rat PC12 cells, Neurosci Lett 317 (1) (2002) 50–52.

[161] J. Zhang, L. Cai, L. Tang, X. Zhang, L. Yang, K. Zheng, A. He, A.R. Boccaccini, J. Wei, J. Zhao, Highly dispersed lithium doped mesoporous silica nanospheres regulating adhesion, proliferation, morphology, ALP activity and osteogenesis related gene expressions of BMSCs, Colloids Surf B Biointerfaces 170 (2018) 563–571.

[162] A.E. Loiselle, S.A. Lloyd, E.M. Paul, G.S. Lewis, H.J. Donahue, Inhibition of GSK-3β rescues the impairments in bone formation and mechanical properties associated with fracture healing in osteoblast selective connexin 43 deficient mice, PLoS One 8 (11) (2013) e81399.

[163] M. Arioka, F. Takahashi-Yanaga, M. Sasaki, T. Yoshihara, S. Morimoto, M. Hirata, Y. Mori, T. Sasaguri, Acceleration of bone regeneration by local application of lithium: Wnt signal-mediated osteoblastogenesis and Wnt signal-independent suppression of osteoclastogenesis, Biochem Pharmacol 90 (4) (2014) 397–405.

[164] T. Pepersack, J. Corvilain, P. Bergmann, Effects of lithium on bone resorption in cultured foetal rat long-bones, Eur J Clin Invest 24 (6) (1994) 400–405.

[165] A.-M. Wu, C. Bisignano, S.L. James, G.G. Abady, A. Abedi, E. Abu-Gharbieh, R.K. Alhassan, V. Alipour, J. Arabloo, M. Asaad, W.N. Asmare, A.F. Awedew, M. Banach, S.K. Banerjee, A. Bijani, T.T.M. Birhanu, S.R. Bolla, L.A. Cámera, J.-C. Chang, D.Y. Cho, M.T. Chung, R.A.S. Couto, X. Dai, L. Dandona, R. Dandona, F. Farzadfar, I. Filip, F. Fischer, A.A. Fomenkov, T.K. Gill, B. Gupta, J.A. Haagsma, A. Haj-Mirzaian, S. Hamidi, S.I. Hay, I.M. Ilic, M.D. Ilic, R.Q. Ivers, M. Jürisson, R. Kalhor, T. Kanchan, T. Kavetskyy, R. Khalilov, E.A. Khan, M. Khan, C.J. Kneib, V. Krishnamoorthy, G.A. Kumar, N. Kumar, R. Lalloo, S. Lasrado, S.S. Lim, Z. Liu, A. Manafi, N. Manafi, R.G. Menezes, T.J. Meretoja, B. Miazgowski, T.R. Miller, Y. Mohammad, A. Mohammadian-Hafshejani, A.H. Mokdad, C.J.L. Murray, M. Naderi, M.D. Naimzada, V.C. Nayak, C.T. Nguyen, R. Nikbakhsh, A.T. Olagunju, N. Otstavnov, S.S. Ostavnov, J.R. Padubidri, J. Pereira, H.Q. Pham, M. Pinheiro, S. Polinder, H. Pourchamani, R. Rabiee, A. Radfar, M.H.U. Rahman, D.L. Rawaf, S. Rawaf, M.R. Saeb, A.M. Samy, L. Sanchez Riera, D.C. Schwebel, S. Shahabi, M.A. Shaikh, A. Soheili, R. Tabarés-Seisdedos, M.R. Tovani-Palone, B.X. Tran, R.S. Travillian, P.R. Valdez, T.J. Vasankari, D.Z. Velazquez, N. Venketasubramanian, G.T. Vu, Z.-J. Zhang, T. Vos, Global, regional, and national burden of bone fractures in 204 countries and territories, 1990–2019: a systematic analysis from the Global Burden of Disease Study 2019, The Lancet Healthy Longevity 2 (9) (2021) e580–e592.

[166] K. Jobin, D.N. Müller, J. Jantsch, C. Kurts, Sodium and its manifold impact on our immune system, Trends in Immunology 42 (6) (2021) 469–479.

[167] A.-B. BALANCE, 15 EVALUATION OF RENAL FUNCTION, Henry's Clinical Diagnosis and Management by Laboratory Methods E-Book (2021) 182.

[168] D.N. Müller, N. Wilck, S. Haase, M. Kleinewietfeld, R.A. Linker, Sodium in the microenvironment regulates immune responses and tissue homeostasis, Nat Rev Immunol 19 (4) (2019) 243–254.

[169] N. Wilck, A. Balogh, L. Markó, H. Bartolomaeus, D.N. Müller, The role of sodium in modulating immune cell function, Nat Rev Nephrol 15 (9) (2019) 546–558.

[170] J.C. Ayus, A.L. Negri, K. Kalantar-Zadeh, M.L. Moritz, Is chronic hyponatremia a novel risk factor for hip fracture in the elderly? Nephrol Dial Transplant 27 (10) (2012) 3725–3731.

[171] A.L. Negri, J.C. Ayus, Hyponatremia and bone disease, Rev Endocr Metab Disord 18 (1) (2017) 67–78.

[172] G. Corona, D. Norello, G. Parenti, A. Sforza, M. Maggi, A. Peri, Hyponatremia, falls and bone fractures: A systematic review and meta-analysis, Clin Endocrinol (Oxf) 89 (4) (2018) 505–513.

[173] Y. Cui, K. Sun, Y. Xiao, X. Li, S. Mo, Y. Yuan, P. Wang, L. Yang, R. Zhang, X. Zhu, High-salt diet accelerates bone loss accompanied by activation of ion channels related to kidney and bone tissue in ovariectomized rats, Ecotoxicol Environ Saf 244 (2022) 114024.

[174] A. Zheng, X. Wang, X. Xin, L. Peng, T. Su, L. Cao, X. Jiang, Promoting lacunar bone regeneration with an injectable hydrogel adaptive to the microenvironment, Bioact Mater 21 (2023) 403–421.

[175] R. Nie, Y. Sun, H. Lv, M. Lu, H. Huangfu, Y. Li, Y. Zhang, D. Wang, L. Wang, Y. Zhou, 3D printing of MXene composite hydrogel scaffolds for photothermal antibacterial activity and bone regeneration in infected bone defect models, Nanoscale 14 (22) (2022) 8112–8129.

[176] D.P. Valido, W.D.G. Júnior, M.E. de Andrade, A.A. Rezende, F.M. de Andrade de Carvalho, R. de Lima, G. das Graças Gomes Trindade, C. de Alcântara Campos, A.M.S. Oliveira, E. de Souza, L.A. Frank, S.S. Guterres, E.M. Sussuchi, C.R.S. Matos, A. Polloni, A.A. de Souza Araújo, F.F. Padilha, P. Severino, E.B. Souto, R.L.C. de Albuquerque Júnior, Otoliths-composed gelatin/sodium alginate scaffolds for bone regeneration, Drug Deliv Transl Res 10 (6) (2020) 1716–1728.

[177] A.A. McDonough, J.H. Youn, Potassium Homeostasis: The Knowns, the Unknowns, and the Health Benefits, Physiology (Bethesda) 32 (2) (2017) 100–111.

[178] K.-Y. Wei, M. Gritter, L. Vogt, M.H. de Borst, J.I. Rotmans, E.J. Hoorn, Dietary potassium and the kidney: Lifesaving physiology, Clinical Kidney Journal 13 (6) (2020) 952–968.

[179] S.W. Lockless, M. Zhou, R. MacKinnon, Structural and thermodynamic properties of selective ion binding in a K+ channel, PLoS biology 5 (5) (2007) e121.

[180] T. Decoursey, K. Chandy, S. Gupta, M. Cahalan, Two types of potassium channels in murine T lymphocytes, The Journal of general physiology 89 (3) (1987) 379–404.

[181] J.H. Kaplan, K-ATPase Biochemistry of Na, Annu Rev Biochem 71 (2002) 511–535.

[182] M.D. Cahalan, H. Wulff, K.G. Chandy, Molecular properties and physiological roles of ion channels in the immune system, J Clin Immunol 21 (4) (2001) 235–252.

[183] R.S. Lewis, M.D. Cahalan, Potassium and calcium channels in lymphocytes, Annual review of immunology 13 (1) (1995) 623–653.

[184] R.S. Lewis, P.E. Ross, M.D. Cahalan, Chloride channels activated by osmotic stress in T lymphocytes, The Journal of general physiology 101 (6) (1993) 801–826.

[185] H. Wulff, P.A. Calabresi, R. Allie, S. Yun, M. Pennington, C. Beeton, K.G. Chandy, The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS, J Clin Invest 111 (11) (2003) 1703–1713.

[186] R. Vicente, A. Escalada, M. Coma, G. Fuster, E. Sánchez-Tilló, C. López-Iglesias, C. Soler, C. Solsona, A. Celada, A. Felipe, Differential voltage-dependent K+ channel responses during proliferation and activation in macrophages, Journal of Biological Chemistry 278 (47) (2003) 46307–46320.

[187] L. Schlichter, N. Sidell, S. Hagiwara, Potassium channels mediate killing by human natural killer cells, Proc Natl Acad Sci U S A 83 (2) (1986) 451–455.

[188] H. Wulff, H.G. Knaus, M. Pennington, K.G. Chandy, K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity, J Immunol 173 (2) (2004) 776–786.

[189] S.H. Kong, J.H. Kim, A.R. Hong, J.H. Lee, S.W. Kim, C.S. Shin, Dietary potassium intake is beneficial to bone health in a low calcium intake population: the Korean National Health and Nutrition Examination Survey (KNHANES) (2008-2011), Osteoporos Int 28 (5) (2017) 1577–1585.

[190] Z. Tang, S. Chen, Y. Ni, R. Zhao, X. Zhu, X. Yang, X. Zhang, Role of Na(+), K(+)-ATPase ion pump in osteoinduction, Acta Biomater 129 (2021) 293–308.

[191] H. Zhang, J. Cheng, Q. Ao, Preparation of Alginate-Based Biomaterials and Their Applications in Biomedicine, Mar Drugs 19 (5) (2021).

[192] K. Loukelis, D. Papadogianni, M. Chatzinikolaidou, Kappa-carrageenan/chitosan/gelatin scaffolds enriched with potassium chloride for bone tissue engineering, Int J Biol Macromol 209 (Pt B) (2022) 1720–1730.

[193] C. Felippe Gonçalves-de-Albuquerque, A. Ribeiro Silva, C. Ignácio da Silva, H. Caire Castro-Faria-Neto, P. Burth, Na/K Pump and Beyond: Na/K-ATPase as a Modulator of Apoptosis and Autophagy, Molecules 22 (4) (2017).

[194] K.G. Chandy, R.S. Norton, Immunology: Channelling potassium to fight cancer, Nature 537 (7621) (2016) 497–499.

[195] M. Miró, J.M. Estela, V.c Cerdà, Application of flowing stream techniques to water analysis: Part III. Metal ions: Alkaline and alkaline-earth metals, elemental and harmful transition metals, and multielemental analysis, Talanta 63 (2) (2004) 201–223.

[196] G. Ye, C. Chen, J. Lin, X. Peng, A. Kumar, D. Liu, J. Liu, Alkali /alkaline earth-based metal-organic frameworks for biomedical applications, Dalton Trans 50 (47) (2021) 17438–17454.

[197] J. Ayuk, N.J. Gittoes, Contemporary view of the clinical relevance of magnesium homeostasis, Ann Clin Biochem 51 (Pt 2) (2014) 179–188.

[198] M. Hoffer, Q.K. Tran, R. Hodgson, M. Atwater, A. Pourmand, Utility of magnesium sulfate for rapid atrial fibrillation in the emergency department: a systematic review and meta-analysis, Eur J Emerg Med 29 (4) (2022) 253–261.

[199] H. Soleimanpour, F. Imani, S. Dolati, M. Soleimanpour, K. Shahsavarinia, Management of pain using magnesium sulphate: a narrative review, Postgrad Med 134 (3) (2022) 260–266.

[200] R. Rizzoli, E. Biver, T.C. Brennan-Speranza, Nutritional intake and bone health, Lancet Diabetes Endocrinol 9 (9) (2021) 606–621.

[201] T. Vilaca, R. Eastell, M. Schini, Osteoporosis in men, Lancet Diabetes Endocrinol 10 (4) (2022) 273–283.

[202] A. Capozzi, G. Scambia, S. Lello, Calcium, vitamin D, vitamin K2, and magnesium supplementation and skeletal health, Maturitas 140 (2020) 55–63.

[203] M. Pilmane, K. Salma-Ancane, D. Loca, J. Locs, L. Berzina-Cimdina, Strontium and strontium ranelate: Historical review of some of their functions, Mater Sci Eng C Mater Biol Appl 78 (2017) 1222–1230.

[204] D. Gregori, G. Giacovelli, C. Minto, B. Barbetta, F. Gualtieri, D. Azzolina, P. Vaghi, L.C. Rovati, Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis, Jama 320 (24) (2018) 2564–2579.

[205] B. Kołodziejska, N. Stępień, J. Kolmas, The Influence of Strontium on Bone Tissue Metabolism and Its Application in Osteoporosis Treatment, Int J Mol Sci 22 (12) (2021).

[206] F.I. Wolf, A. Cittadini, Chemistry and biochemistry of magnesium, Mol Aspects Med 24 (1-3) (2003) 3–9.

[207] J. Hathcock, Vitamins and minerals: efficacy and safety, The American journal of clinical nutrition 66 (2) (1997) 427–437.

[208] J.A. Cowan, Inorganic biochemistry: an introduction, John Wiley & Sons 1997.

[209] J.H. de Baaij, J.G. Hoenderop, R.J. Bindels, Magnesium in man: implications for health and disease, Physiol Rev 95 (1) (2015) 1–46.

[210] I. Inoue, Lipid metabolism and magnesium, Clinical calcium 15 (11) (2005) 65–76.

[211] A.M. Romani, Magnesium in health and disease, Interrelations between essential metal ions and human diseases (2013) 49–79.

[212] M. Monné, L. Daddabbo, L.C. Giannossa, M.C. Nicolardi, L. Palmieri, D.V. Miniero, A. Mangone, F. Palmieri, Mitochondrial ATP-Mg/phosphate carriers transport divalent inorganic cations in complex with ATP, J Bioenerg Biomembr 49 (5) (2017) 369–380.

[213] H. Hou, L. Wang, T. Fu, M. Papasergi, D.I. Yule, H. Xia, Magnesium Acts as a Second Messenger in the Regulation of NMDA Receptor-Mediated CREB Signaling in Neurons, Mol Neurobiol 57 (6) (2020) 2539–2550.

[214] X. Shi, L. Zhu, S. Wang, W. Zhu, Q. Li, J. Wei, D. Feng, M. Liu, Y. Chen, X. Sun, H. Lu, X. Lv, Magnesium Hydride Ameliorates Endotoxin-Induced Acute Respiratory Distress Syndrome by Inhibiting Inflammation, Oxidative Stress, and Cell Apoptosis, Oxid Med Cell Longev 2022 (2022) 5918954.

[215] L. Zhang, C. Yang, J. Li, Y. Zhu, X. Zhang, High extracellular magnesium inhibits mineralized matrix deposition and modulates intracellular calcium signaling in human bone marrow-derived mesenchymal stem cells, Biochem Biophys Res Commun 450 (4) (2014) 1390–1395.

[216] K. Brandao, F. Deason-Towne, A.L. Perraud, C. Schmitz, The role of Mg2+ in immune cells, Immunol Res 55 (1-3) (2013) 261–269.

[217] A. Goytain, G.A. Quamme, Identification and characterization of a novel mammalian Mg2+ transporter with channel-like properties, BMC Genomics 6 (2005) 48.

[218] V. Trapani, N. Shomer, E. Rajcan-Separovic, The role of MAGT1 in genetic syndromes, Magnesium research 28 (2) (2015) 46–55.

[219] C. Schmitz, F. Deason, A.L. Perraud, Molecular components of vertebrate Mg2+-homeostasis regulation, Magnes Res 20 (1) (2007) 6–18.

[220] T. Voets, B. Nilius, S. Hoefs, A.W. van der Kemp, G. Droogmans, R.J. Bindels, J.G. Hoenderop, TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption, J Biol Chem 279 (1) (2004) 19–25.

[221] C. Schmitz, M.V. Dorovkov, X. Zhao, B.J. Davenport, A.G. Ryazanov, A.L. Perraud, The channel kinases TRPM6 and TRPM7 are functionally nonredundant, J Biol Chem 280 (45) (2005) 37763–37771.

[222] F.I. Wolf, V. Trapani, Magnesium and its transporters in cancer: a novel paradigm in tumour development, Clin Sci (Lond) 123 (7) (2012) 417–427.

[223] B. Zhang, J. Li, L. He, H. Huang, J. Weng, Bio-surface coated titanium scaffolds with cancellous bone-like biomimetic structure for enhanced bone tissue regeneration, Acta Biomaterialia 114 (2020) 431–448.

[224] T. Schilling, F. Miralles, C. Eder, TRPM7 regulates proliferation and polarisation of macrophages, J Cell Sci 127 (Pt 21) (2014) 4561–4566.

[225] K.P. Schlingmann, S. Weber, M. Peters, L. Niemann Nejsum, H. Vitzthum, K. Klingel, M. Kratz, E. Haddad, E. Ristoff, D. Dinour, M. Syrrou, S. Nielsen, M. Sassen, S. Waldegger, H.W. Seyberth, M. Konrad, Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family, Nat Genet 31 (2) (2002) 166–170.

[226] R. Chokshi, M. Matsushita, J.A. Kozak, Detailed examination of Mg2+ and pH sensitivity of human TRPM7 channels, Am J Physiol Cell Physiol 302 (7) (2012) C1004–C1011.

[227] W. Qiao, K.H.M. Wong, J. Shen, W. Wang, J. Wu, J. Li, Z. Lin, Z. Chen, J.P. Matinlinna, Y. Zheng, S. Wu, X. Liu, K.P. Lai, Z. Chen, Y.W. Lam, K.M.C. Cheung, K.W.K. Yeung, TRPM7 kinase-mediated immunomodulation in macrophage plays a central role in magnesium ion-induced bone regeneration, Nat Commun 12 (1) (2021) 2885.

[228] F.Y. Li, B. Chaigne-Delalande, C. Kanellopoulou, J.C. Davis, H.F. Matthews, D.C. Douek, J.I. Cohen, G. Uzel, H.C. Su, M.J. Lenardo, Second messenger role for Mg2+ revealed by human T-cell immunodeficiency, Nature 475 (7357) (2011) 471–476.

[229] S. Vardhana, M.L. Dustin, Magnesium for T cells: strong to the finish!, Trends Immunol 43 (4) (2022) 277–279.

[230] Y. Kang, C. Xu, L. Meng, X. Dong, M. Qi, D. Jiang, Exosome-functionalized magnesium-organic framework-based scaffolds with osteogenic, angiogenic and anti-inflammatory properties for accelerated bone regeneration, Bioact Mater 18 (2022) 26–41.

[231] X. Zhang, P. Huang, G. Jiang, M. Zhang, F. Yu, X. Dong, L. Wang, Y. Chen, W. Zhang, Y. Qi, W. Li, H. Zeng, A novel magnesium ion-incorporating dual-crosslinked hydrogel to improve bone scaffold-mediated osteogenesis and angiogenesis, Mater Sci Eng C Mater Biol Appl 121 (2021) 111868.

[232] Y. Chen, W. Sheng, J. Lin, C. Fang, J. Deng, P. Zhang, M. Zhou, P. Liu, J. Weng, F. Yu, D. Wang, B. Kang, H. Zeng, Magnesium Oxide Nanoparticle Coordinated Phosphate-Functionalized Chitosan Injectable Hydrogel for Osteogenesis and Angiogenesis in Bone Regeneration, ACS Appl Mater Interfaces 14 (6) (2022) 7592–7608.

[233] Z. Zhao, G. Li, H. Ruan, K. Chen, Z. Cai, G. Lu, R. Li, L. Deng, M. Cai, W. Cui, Capturing Magnesium Ions via Microfluidic Hydrogel Microspheres for Promoting Cancellous Bone Regeneration, ACS Nano 15 (8) (2021) 13041–13054.

[234] X. Wei, W. Zhou, Z. Tang, H. Wu, Y. Liu, H. Dong, N. Wang, H. Huang, S. Bao, L. Shi, X. Li, Y. Zheng, Z. Guo, Magnesium surface-activated 3D printed porous PEEK scaffolds for in vivo osseointegration by promoting angiogenesis and osteogenesis, Bioact Mater 20 (2023) 16–28.

[235] M. Wang, Y. Yu, K. Dai, Z. Ma, Y. Liu, J. Wang, C. Liu, Improved osteogenesis and angiogenesis of magnesium-doped calcium phosphate cement via macrophage immunomodulation, Biomater Sci 4 (11) (2016) 1574–1583.

[236] T. Hu, H. Xu, C. Wang, H. Qin, Z. An, Magnesium enhances the chondrogenic differentiation of mesenchymal stem cells by inhibiting activated macrophage-induced inflammation, Sci Rep 8 (1) (2018) 3406.

[237] Y. Lai, Y. Li, H. Cao, J. Long, X. Wang, L. Li, C. Li, Q. Jia, B. Teng, T. Tang, J. Peng, D. Eglin, M. Alini, D.W. Grijpma, G. Richards, L. Qin, Osteogenic magnesium incorporated into PLGA/TCP porous scaffold by 3D printing for repairing challenging bone defect, Biomaterials 197 (2019) 207–219.

[238] Z. Zhai, X. Qu, H. Li, K. Yang, P. Wan, L. Tan, Z. Ouyang, X. Liu, B. Tian, F. Xiao, W. Wang, C. Jiang, T. Tang, Q. Fan, A. Qin, K. Dai, The effect of metallic magnesium degradation products on osteoclast-induced osteolysis and attenuation of NF-κB and NFATc1 signaling, Biomaterials 35 (24) (2014) 6299–6310.

[239] Y. Zhang, J. Xu, Y.C. Ruan, M.K. Yu, M. O'Laughlin, H. Wise, D. Chen, L. Tian, D. Shi, J. Wang, S. Chen, J.Q. Feng, D.H. Chow, X. Xie, L. Zheng, L. Huang, S. Huang, K. Leung, N. Lu, L. Zhao, H. Li, D. Zhao, X. Guo, K. Chan, F. Witte, H.C. Chan, Y. Zheng, L. Qin, Implant-derived magnesium induces local neuronal production of CGRP to improve bone-fracture healing in rats, Nat Med 22 (10) (2016) 1160–1169.

[240] J.A. Maier, S. Castiglioni, L. Locatelli, M. Zocchi, A. Mazur, Magnesium and inflammation: Advances and perspectives, Semin Cell Dev Biol 115 (2021) 37–44.

[241] D.A. Bushinsky, R.D. Monk, Electrolyte quintet: Calcium, Lancet 352 (9124) (1998) 306–311.

[242] P. Kroneck, M.S. Torres, Metals, Microbes, and Minerals-The Biogeochemical Side of Life, Walter de Gruyter GmbH & Co KG, 2021.

[243] M. Vig, J.P. Kinet, Calcium signaling in immune cells, Nat Immunol 10 (1) (2009) 21–27.

[244] M.J. Berridge, P. Lipp, M.D. Bootman, The versatility and universality of calcium signalling, Nature reviews Molecular cell biology 1 (1) (2000) 11–21.

[245] E. Carafoli, Calcium pump of the plasma membrane, Physiological reviews 71 (1) (1991) 129–153.

[246] M. Oh-hora, A. Rao, Calcium signaling in lymphocytes, Curr Opin Immunol 20 (3) (2008) 250–258.

[247] O. Mignen, J.L. Thompson, T.J. Shuttleworth, Orai1 subunit stoichiometry of the mammalian CRAC channel pore, The Journal of physiology 586 (2) (2008) 419–425.

[248] S. Feske, H. Wulff, E.Y. Skolnik, Ion channels in innate and adaptive immunity, Annual review of immunology 33 (2015) 291.

[249] K.-D. Kim, S. Srikanth, Y.-V. Tan, M.-K. Yee, M. Jew, R. Damoiseaux, M.E. Jung, S. Shimizu, D.S. An, B. Ribalet, Calcium signaling via Orai1 is essential for induction of the nuclear orphan receptor pathway to drive Th17 differentiation, The Journal of Immunology 192 (1) (2014) 110–122.

[250] S. Liang, X. Deng, G. Xu, X. Xiao, M. Wang, X. Guo, P.a. Ma, Z. Cheng, D. Zhang, J. Lin, A novel Pt–TiO2 heterostructure with oxygen-deficient layer as bilaterally enhanced sonosensitizer for synergistic chemo-sonodynamic cancer therapy, Advanced Functional Materials 30 (13) (2020) 1908598.

[251] M. Vaeth, M. Maus, S. Klein-Hessling, E. Freinkman, J. Yang, M. Eckstein, S. Cameron, S.E. Turvey, E. Serfling, F. Berberich-Siebelt, R. Possemato, S. Feske, Store-Operated Ca(2+) Entry Controls Clonal Expansion of T Cells through Metabolic Reprogramming, Immunity 47 (4) (2017) 664–679 e6.

[252] M. Vaeth, S. Kahlfuss, S. Feske, CRAC Channels and Calcium Signaling in T Cell–Mediated Immunity, Trends Immunol 41 (10) (2020) 878–901.

[253] B. Dawson-Hughes, Calcium supplementation and bone loss: a review of controlled clinical trials, Am J Clin Nutr 54 (1 Suppl) (1991) 274s-280s.

[254] W.T. Simonet, J.T. Bronk, M.R. Pinto, E.A. Williams, T.H. Meadows, P.J. Kelly, Cortical and cancellous bone: age-related changes in morphologic features, fluid spaces, and calcium homeostasis in dogs, Mayo Clin Proc 63 (2) (1988) 154–160.

[255] L.G. Raisz, Pathogenesis of osteoporosis: concepts, conflicts, and prospects, J Clin Invest 115 (12) (2005) 3318–3325.

[256] J. Zhang, D. Tong, H. Song, R. Ruan, Y. Sun, Y. Lin, J. Wang, L. Hou, J. Dai, J. Ding, H. Yang, Osteoimmunity-Regulating Biomimetically Hierarchical Scaffold for Augmented Bone Regeneration, Adv Mater 34 (36) (2022) e2202044.

[257] A. Shanaghi, B. Mehrjou, Z. Ahmadian, A.R. Souri, P.K. Chu, Enhanced corrosion resistance, antibacterial properties, and biocompatibility by hierarchical hydroxyapatite/ciprofloxacin-calcium phosphate coating on nitrided NiTi alloy, Mater Sci Eng C Mater Biol Appl 118 (2021) 111524.

[258] E.C. Rodríguez-Merchán, Bone Healing Materials in the Treatment of Recalcitrant Nonunions and Bone Defects, Int J Mol Sci 23 (6) (2022).

[259] Y. Arfat, A. Rani, W. Jingping, C.H. Hocart, Calcium homeostasis during hibernation and in mechanical environments disrupting calcium homeostasis, J Comp Physiol B 190 (1) (2020) 1–16.

[260] K. Zhang, Y. Zhou, C. Xiao, W. Zhao, H. Wu, J. Tang, Z. Li, S. Yu, X. Li, L. Min, Z. Yu, G. Wang, L. Wang, K. Zhang, X. Yang, X. Zhu, C. Tu, X. Zhang, Application of hydroxyapatite nanoparticles in tumor-associated bone segmental defect, Sci Adv 5 (8) (2019) eaax6946.

[261] Z. Chen, C. Wu, J. Yuen, T. Klein, R. Crawford, Y. Xiao, Influence of osteocytes in the in vitro and in vivo β-tricalcium phosphate-stimulated osteogenesis, J Biomed Mater Res A 102 (8) (2014) 2813–2823.

[262] Z. Chen, C. Wu, W. Gu, T. Klein, R. Crawford, Y. Xiao, Osteogenic differentiation of bone marrow MSCs by β-tricalcium phosphate stimulating macrophages via BMP2 signalling pathway, Biomaterials 35 (5) (2014) 1507–1518.

[263] S. Rajagopal, M. Ponnusamy, S. Rajagopal, M. Ponnusamy, Calcium ion in biological systems, Calcium Signaling: From Physiology to Diseases (2017) 1–14.

[264] N.S. Poluehktov, V.T. Mishchenko, L.I. Kononenko, S.V. Bel'tyukova, Analytical chemistry of strontium, Nauka, USSR, 1978.

[265] P.A. Neighbour, H.S. Huberman, Y. Kress, Human large granular lymphocytes and natural killing ultrastructural studies of strontium-induced degranulation, Eur J Immunol 12 (7) (1982) 588–595.

[266] J. You, Y. Zhang, Y. Zhou, Strontium Functionalized in Biomaterials for Bone Tissue Engineering: A Prominent Role in Osteoimmunomodulation, Front Bioeng Biotechnol 10 (2022) 928799.

[267] T. Li, H. He, Z. Yang, J. Wang, Y. Zhang, G. He, J. Huang, D. Song, J. Ni, X. Zhou, J. Zhu, M. Ding, Strontium-doped gelatin scaffolds promote M2 macrophage switch and angiogenesis through modulating the polarization of neutrophils, Biomater Sci 9 (8) (2021) 2931–2946.

[268] A.H. Lourenço, A.L. Torres, D.P. Vasconcelos, C. Ribeiro-Machado, J.N. Barbosa, M.A. Barbosa, C.C. Barrias, C.C. Ribeiro, Osteogenic, anti-osteoclastogenic and immunomodulatory properties of a strontium-releasing hybrid scaffold for bone repair, Mater Sci Eng C Mater Biol Appl 99 (2019) 1289–1303.

[269] X. Shen, K. Fang, K.H. Ru Yie, Z. Zhou, Y. Shen, S. Wu, Y. Zhu, Z. Deng, P. Ma, J. Ma, J. Liu, High proportion strontium-doped micro-arc oxidation coatings enhance early osseointegration of titanium in osteoporosis by anti-oxidative stress pathway, Bioact Mater 10 (2022) 405–419.

[270] N.H. Lee, M.S. Kang, T.H. Kim, D.S. Yoon, N. Mandakhbayar, S.B. Jo, H.S. Kim, J.C. Knowles, J.H. Lee, H.W. Kim, Dual actions of osteoclastic-inhibition and os-

teogenic-stimulation through strontium-releasing bioactive nanoscale cement imply biomaterial-enabled osteoporosis therapy, Biomaterials 276 (2021) 121025.

[271] W. Lu, C. Zhou, Y. Ma, J. Li, J. Jiang, Y. Chen, L. Dong, F. He, Improved osseointegration of strontium-modified titanium implants by regulating angiogenesis and macrophage polarization, Biomater Sci 10 (9) (2022) 2198–2214.

[272] U. Krämer, I.N. Talke, M. Hanikenne, Transition metal transport, FEBS letters 581 (12) (2007) 2263–2272.

[273] D. Crans, P. Chatterjee, Vanadium biochemistry, Comprehensive Inorganic Chemistry II From Elements to Applications, 2nd ed.; Reedijk, J., Poeppelmeier, KR, Eds (2013) 323-342.

[274] A. Scibior, L. Pietrzyk, Z. Plewa, A. Skiba, Vanadium: Risks and possible benefits in the light of a comprehensive overview of its pharmacotoxicological mechanisms and multi-applications with a summary of further research trends, J Trace Elem Med Biol 61 (2020) 126508.

[275] D. Tripathi, V. Mani, R.P. Pal, Vanadium in biosphere and its role in biological processes, Biological trace element research 186 (1) (2018) 52–67.

[276] O. Tsave, S. Petanidis, E. Kioseoglou, M.P. Yavropoulou, J.G. Yovos, D. Anestakis, A. Tsepa, A. Salifoglou, Role of Vanadium in Cellular and Molecular Immunology: Association with Immune-Related Inflammation and Pharmacotoxicology Mechanisms, Oxid Med Cell Longev 2016 (2016) 4013639.

[277] H. Fickl, A.J. Theron, H. Grimmer, J. Oommen, G.J. Ramafi, H.C. Steel, S.S. Visser, R. Anderson, Vanadium promotes hydroxyl radical formation by activated human neutrophils, Free Radical Biology and Medicine 40 (1) (2006) 146–155.

[278] D.G. Barceloux, D. Barceloux, Vanadium, Journal of Toxicology: Clinical Toxicology 37 (2) (1999) 265–278.

[279] N.R. Council, Mineral tolerance of domestic animals, National Academies Press (1980).

[280] D.A. Barrio, S.B. Etcheverry, Vanadium and bone development: putative signaling pathways, Can J Physiol Pharmacol 84 (7) (2006) 677–686.

[281] J. Li, J. Li, Y. Wei, N. Xu, J. Li, X. Pu, J. Wang, Z. Huang, X. Liao, G. Yin, Ion release behavior of vanadium-doped mesoporous bioactive glass particles and the effect of the released ions on osteogenic differentiation of BMSCs via the FAK/MAPK signaling pathway, J Mater Chem B 9 (37) (2021) 7848–7865.

[282] A. Scibior, A. Adamczyk, R. Mroczka, I. Niedźwiecka, D. Gołębiowska, E. Fornal, Effects of vanadium (V) and magnesium (Mg) on rat bone tissue: mineral status and micromorphology. Consequences of V-Mg interactions, Metallomics 6 (12) (2014) 2260–2278.

[283] G. Demazeau, B. Buffat, M. Pouchard, P. Hagenmuller, Recent developments in the field of high oxidation states of transition elements in oxides stabilization of Six-coordinated Iron (V), Zeitschrift fuer Anorganische und Allgemeine Chemie (1982) (1950) 491.

[284] T. Ganz, Systemic iron homeostasis, Physiol Rev 93 (4) (2013) 1721–1741.

[285] J.M. Bradley, N.E. Le Brun, G.R. Moore, Ferritins: furnishing proteins with iron, J Biol Inorg Chem 21 (1) (2016) 13–28.

[286] D.A. Gell, Structure and function of haemoglobins, Blood Cells Mol Dis 70 (2018) 13–42.

[287] M. Piccioli, The biogenesis of iron-sulfur proteins: from cellular biology to molecular aspects, J Biol Inorg Chem 23 (4) (2018) 493–494.

[288] P.T. Gomme, K.B. McCann, J. Bertolini, Transferrin: structure, function and potential therapeutic actions, Drug Discov Today 10 (4) (2005) 267–273.

[289] G.A. Ordway, D.J. Garry, Myoglobin: an essential hemoprotein in striated muscle, J Exp Biol 207 (Pt 20) (2004) 3441–3446.

[290] J. Finkelstein, Metalloproteins, Nature 460 (7257) (2009) 813.

[291] C. Glorieux, P.B. Calderon, Catalase, a remarkable enzyme: targeting the oldest antioxidant enzyme to find a new cancer treatment approach, Biol Chem 398 (10) (2017) 1095–1108.

[292] I. Feussner, C. Wasternack, The lipoxygenase pathway, Annu Rev Plant Biol 53 (2002) 275–297.

[293] R.J. Ward, D.T. Dexter, R.R. Crichton, Iron, Neuroinflammation and Neurodegeneration, Int J Mol Sci 23 (13) (2022).

[294] S. Dutt, I. Hamza, T.B. Bartnikas, Molecular Mechanisms of Iron and Heme Metabolism, Annu Rev Nutr 42 (2022) 311–335.

[295] V.M. Boradia, M. Raje, C.I. Raje, Protein moonlighting in iron metabolism: glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Biochem Soc Trans 42 (6) (2014) 1796–1801.

[296] M. Kruszewski, Labile iron pool: the main determinant of cellular response to oxidative stress, Mutat Res 531 (1-2) (2003) 81–92.

[297] O. Kakhlon, Z.I. Cabantchik, The labile iron pool: characterization, measurement, and participation in cellular processes(1), Free Radic Biol Med 33 (8) (2002) 1037–1046.

[298] K. Orino, K. Watanabe, Molecular, physiological and clinical aspects of the iron storage protein ferritin, Vet J 178 (2) (2008) 191–201.

[299] E. Nemeth, T. Ganz, Hepcidin-Ferroportin Interaction Controls Systemic Iron Homeostasis, Int J Mol Sci 22 (12) (2021).

[300] J. Petrak, D. Vyoral, Hephaestin–a ferroxidase of cellular iron export, Int J Biochem Cell Biol 37 (6) (2005) 1173–1178.

[301] N.E. Hellman, J.D. Gitlin, Ceruloplasmin metabolism and function, Annu Rev Nutr 22 (2002) 439–458.

[302] D. Haschka, A. Hoffmann, G. Weiss, Iron in immune cell function and host defense, Semin Cell Dev Biol 115 (2021) 27–36.

[303] J. Yang, Q. Li, Y. Feng, Y. Zeng, Iron Deficiency and Iron Deficiency Anemia: Potential Risk Factors in Bone Loss, Int J Mol Sci 24 (8) (2023).

[304] M. Nairz, G. Weiss, Iron in infection and immunity, Mol Aspects Med 75 (2020) 100864.

[305] S. Ni, Y. Yuan, Y. Kuang, X. Li, Iron Metabolism and Immune Regulation, Front Immunol 13 (2022) 816282.

[306] M.A. Llamas, A. Sánchez-Jiménez, Iron Homeostasis in Pseudomonas aeruginosa: Targeting Iron Acquisition and Storage as an Antimicrobial Strategy, Adv Exp Med Biol 1386 (2022) 29–68.

[307] Z. Zhang, X. He, C. Zhou, M. Reaume, M. Wu, B. Liu, B.P. Lee, Iron Magnetic Nanoparticle-Induced ROS Generation from Catechol-Containing Microgel for Environmental and Biomedical Applications, ACS Appl Mater Interfaces 12 (19) (2020) 21210–21220.

[308] N.E. Putra, K.G.N. Borg, P.J. Diaz-Payno, M.A. Leeflang, M. Klimopoulou, P. Taheri, J.M.C. Mol, L.E. Fratila-Apachitei, Z. Huan, J. Chang, J. Zhou, A.A. Zadpoor, Additive manufacturing of bioactive and biodegradable porous iron-akermanite composites for bone regeneration, Acta Biomater 148 (2022) 355–373.

[309] T. Ganz, E. Nemeth, Iron homeostasis in host defence and inflammation, Nat Rev Immunol 15 (8) (2015) 500–510.

[310] A.R. Battersby, Biosynthesis of vitamin B12, Accounts of chemical research 26 (1) (1993) 15–21.

[311] M. Kobayashi, S. Shimizu, Cobalt proteins, European Journal of Biochemistry 261 (1) (1999) 1–9.

[312] L.O. Simonsen, H. Harbak, P. Bennekou, Cobalt metabolism and toxicology—a brief update, Science of the Total Environment 432 (2012) 210–215.

[313] M. Akbar, J.M. Brewer, M.H. Grant, Effect of chromium and cobalt ions on primary human lymphocytes in vitro, Journal of immunotoxicology 8 (2) (2011) 140–149.

[314] H. Lawrence, D.J. Deehan, J.P. Holland, S.A. Anjum, A.E. Mawdesley, J.A. Kirby, A.J. Tyson-Capper, Cobalt ions recruit inflammatory cells in vitro through human Toll-like receptor 4, Biochemistry and biophysics reports 7 (2016) 374–378.

[315] K. Chamaon, P. Schönfeld, F. Awiszus, J. Bertrand, C.H. Lohmann, Ionic cobalt but not metal particles induces ROS generation in immune cells in vitro, Journal of Biomedical Materials Research Part B: Applied Biomaterials 107 (4) (2019) 1246–1253.

[316] L. Diez-Tercero, L.M. Delgado, E. Bosch-Rue, R.A. Perez, Evaluation of the immunomodulatory effects of cobalt, copper and magnesium ions in a pro inflammatory environment, Sci Rep 11 (1) (2021) 11707.

[317] X. Yang, C. Zhang, T. Zhang, J. Xiao, Cobalt-doped Ti surface promotes immunomodulation, Biomedical Materials 17 (2) (2022) 025003.

[318] M. Kumanto, E.L. Paukkeri, R. Nieminen, E. Moilanen, Cobalt (II) chloride modifies the phenotype of macrophage activation, Basic & Clinical Pharmacology & Toxicology 121 (2) (2017) 98–105.

[319] J. Xu, J. Yang, A. Nyga, M. Ehteramyan, A. Moraga, Y. Wu, L. Zeng, M.M. Knight, J.C. Shelton, Cobalt (II) ions and nanoparticles induce macrophage retention by ROS-mediated down-regulation of RhoA expression, Acta biomaterialia 72 (2018) 434–446.

[320] Z. Deng, B. Lin, Z. Jiang, W. Huang, J. Li, X. Zeng, H. Wang, D. Wang, Y. Zhang, Hypoxia-Mimicking Cobalt-Doped Borosilicate Bioactive Glass Scaffolds with Enhanced Angiogenic and Osteogenic Capacity for Bone Regeneration, Int J Biol Sci 15 (6) (2019) 1113–1124.

[321] Y. Zheng, Y. Yang, Y. Deng, Dual therapeutic cobalt-incorporated bioceramics accelerate bone tissue regeneration, Mater Sci Eng C Mater Biol Appl 99 (2019) 770–782.

[322] G. Liu, X. Wang, X. Zhou, L. Zhang, J. Mi, Z. Shan, B. Huang, Z. Chen, Z. Chen, Modulating the cobalt dose range to manipulate multisystem cooperation in bone environment: a strategy to resolve the controversies about cobalt use for orthopedic applications, Theranostics 10 (3) (2020) 1074.

[323] A. Minchenko, J. Caro, Regulation of endothelin-1 gene expression in human microvascular endothelial cells by hypoxia and cobalt: role of hypoxia responsive element, Mol Cell Biochem 208 (1-2) (2000) 53–62.

[324] T. Tanaka, I. Kojima, T. Ohse, J.R. Ingelfinger, S. Adler, T. Fujita, M. Nangaku, Cobalt promotes angiogenesis via hypoxia-inducible factor and protects tubulointerstitium in the remnant kidney model, Lab Invest 85 (10) (2005) 1292–1307.

[325] L. Leyssens, B. Vinck, C. Van Der Straeten, F. Wuyts, L. Maes, Cobalt toxicity in humans-A review of the potential sources and systemic health effects, Toxicology 387 (2017) 43–56.

[326] C. Petrarca, A.M. Poma, G. Vecchiotti, G. Bernardini, Q. Niu, A.G. Cattaneo, M. Di Gioacchino, E. Sabbioni, Cobalt magnetic nanoparticles as theranostics: Conceivable or forgettable? Nanotechnology Reviews 9 (1) (2020) 1522–1538.

[327] W.F. Smith, J. Hashemi, Foundations of materials science and engineering, Mcgraw-Hill Publishing, 2006.

[328] K. Vest, H. Hashemi, P. Cobine, Metallomics and the Cell. Metal Ions in Life Sciences: Chapter 13 The Copper Metallome in Eukaryotic Cells, Springer (10) (2013) 978–994.

[329] B.-E. Kim, T. Nevitt, D.J. Thiele, Mechanisms for copper acquisition, distribution and regulation, Nature chemical biology 4 (3) (2008) 176–185.

[330] V. Culotta, Cell biology of copper, J Biol Inorg Chem 15 (1) (2010) 1–2.

[331] M. Araya, M. Olivares, F. Pizarro, Copper in human health, International Journal of Environment and Health 1 (4) (2007) 608–620.

[332] S.S. Percival, Copper and immunity, Am J Clin Nutr 67 (5 Suppl) (1998) 1064s-1068s.

[333] L.A. Videla, V. Fernández, G. Tapia, P. Varela, Oxidative stress-mediated hepatotoxicity of iron and copper: role of Kupffer cells, Biometals 16 (1) (2003) 103–111.

[334] T.R. Halfdanarson, N. Kumar, C.Y. Li, R.L. Phyliky, W.J. Hogan, Hematological manifestations of copper deficiency: a retrospective review, Eur J Haematol 80 (6) (2008) 523–531.

[335] D.G. Jones, N.F. Suttle, The effect of copper deficiency on the resistance of mice to infection with Pasteurella haemolytica, J Comp Pathol 93 (1) (1983) 143–149.

[336] R. Boyne, J.R. Arthur, Effects of selenium and copper deficiency on neutrophil function in cattle, J Comp Pathol 91 (2) (1981) 271–276.

[337] S. Maggini, E.S. Wintergerst, S. Beveridge, D.H. Hornig, Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellu-

lar and humoral immune responses, British journal of nutrition 98 (S1) (2007) S29–S35.

[338] H.H. Dollwet, J.R. Sorenson, Roles of copper in bone maintenance and healing, Biol Trace Elem Res 18 (1988) 39–48.

[339] D.M. Medeiros, Copper, iron, and selenium dietary deficiencies negatively impact skeletal integrity: A review, Exp Biol Med (Maywood) 241 (12) (2016) 1316–1322.

[340] R. Lin, C. Deng, X. Li, Y. Liu, M. Zhang, C. Qin, Q. Yao, L. Wang, C. Wu, Copper-incorporated bioactive glass-ceramics inducing anti-inflammatory phenotype and regeneration of cartilage/bone interface, Theranostics 9 (21) (2019) 6300–6313.

[341] G.L. Semenza, Signal transduction to hypoxia-inducible factor 1, Biochemical pharmacology 64 (5-6) (2002) 993–998.

[342] W. Feng, F. Ye, W. Xue, Z. Zhou, Y.J. Kang, Copper regulation of hypoxia-inducible factor-1 activity, Molecular pharmacology 75 (1) (2009) 174–182.

[343] M. Ivan, K. Kondo, H. Yang, W. Kim, J. Valiando, M. Ohh, A. Salic, J.M. Asara, W.S. Lane, W.G. Kaelin Jr, HIFα targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing, Science 292 (5516) (2001) 464–468.

[344] D. Mitra, E.T. Kang, K.G. Neoh, Antimicrobial Copper-Based Materials and Coatings: Potential Multifaceted Biomedical Applications, ACS Appl Mater Interfaces 12 (19) (2020) 21159–21182.

[345] A. Jacobs, G. Renaudin, C. Forestier, J.M. Nedelec, S. Descamps, Biological properties of copper-doped biomaterials for orthopedic applications: A review of antibacterial, angiogenic and osteogenic aspects, Acta Biomater 117 (2020) 21–39.

[346] Q. Shen, Y. Qi, Y. Kong, H. Bao, Y. Wang, A. Dong, H. Wu, Y. Xu, Advances in Copper-Based Biomaterials With Antibacterial and Osteogenic Properties for Bone Tissue Engineering, Front Bioeng Biotechnol 9 (2021) 795425.

[347] Z. Zhang, Y. Wang, W. Teng, X. Zhou, Y. Ye, H. Zhou, H. Sun, F. Wang, A. Liu, P. Lin, W. Cui, X. Yu, Y. Wu, Z. Ye, An orthobiologics-free strategy for synergistic photocatalytic antibacterial and osseointegration, Biomaterials 274 (2021) 120853.

[348] M. Shi, Z. Chen, S. Farnaghi, T. Friis, X. Mao, Y. Xiao, C. Wu, Copper-doped mesoporous silica nanospheres, a promising immunomodulatory agent for inducing osteogenesis, Acta Biomater 30 (2016) 334–344.

[349] A. Noori, M. Hoseinpour, S. Kolivand, N. Lotfibakhshaiesh, M. Azami, J. Ai, S. Ebrahimi-Barough, Synergy effects of copper and L-arginine on osteogenic, angiogenic, and antibacterial activities, Tissue Cell 77 (2022) 101849.

[350] L.R. Rivera, A. Cochis, S. Biser, E. Canciani, S. Ferraris, L. Rimondini, A.R. Boccaccini, Antibacterial, pro-angiogenic and pro-osteointegrative zein-bioactive glass/copper based coatings for implantable stainless steel aimed at bone healing, Bioact Mater 6 (5) (2021) 1479–1490.

[351] C. Doguer, J.H. Ha, J.F. Collins, Intersection of Iron and Copper Metabolism in the Mammalian Intestine and Liver, Compr Physiol 8 (4) (2018) 1433–1461.

[352] S.L. Stafford, N.J. Bokil, M.E. Achard, R. Kapetanovic, M.A. Schembri, A.G. McEwan, M.J. Sweet, Metal ions in macrophage antimicrobial pathways: emerging roles for zinc and copper, Biosci Rep 33 (4) (2013).

[353] H.T. Shi, Z.H. Huang, T.Z. Xu, A.J. Sun, J.B. Ge, New diagnostic and therapeutic strategies for myocardial infarction via nanomaterials, EBioMedicine 78 (2022) 103968.

[354] F.C. Porter, Zinc Handbook: Properties, Processing, and Use In Design, 1st ed., Taylor & Francis Group, 1991.

[355] W. Maret, Zinc and human disease, Interrelations between essential metal ions and human diseases (2013) 389–414.

[356] B.T. Muyssen, K.A. De Schamphelaere, C.R. Janssen, Mechanisms of chronic waterborne Zn toxicity in Daphnia magna, Aquatic toxicology 77 (4) (2006) 393–401.

[357] S.R. Lee, S.J. Noh, J.R. Pronto, Y.J. Jeong, H.K. Kim, I.S. Song, Z. Xu, H.Y. Kwon, S.C. Kang, E.H. Sohn, K.S. Ko, B.D. Rhee, N. Kim, J. Han, The Critical Roles of Zinc: Beyond Impact on Myocardial Signaling, Korean J Physiol Pharmacol 19 (5) (2015) 389–399.

[358] B. Kim, W.W. Lee, Regulatory Role of Zinc in Immune Cell Signaling, Mol Cells 44 (5) (2021) 335–341.

[359] P. Bonaventura, G. Benedetti, F. Albarède, P. Miossec, Zinc and its role in immunity and inflammation, Autoimmunity reviews 14 (4) (2015) 277–285.

[360] A.S. Prasad, Zinc in human health: effect of zinc on immune cells, Molecular medicine 14 (5) (2008) 353–357.

[361] H. Haase, L. Rink, Zinc signals and immune function, Biofactors 40 (1) (2014) 27–40.

[362] M.E. Leibbrandt, J. Koropatnick, Activation of human monocytes with lipopolysaccharide induces metallothionein expression and is diminished by zinc, Toxicology and applied pharmacology 124 (1) (1994) 72–81.

[363] H. Haase, J.L. Ober-Blöbaum, G. Engelhardt, S. Hebel, A. Heit, H. Heine, L. Rink, Zinc signals are essential for lipopolysaccharide-induced signal transduction in monocytes, The Journal of Immunology 181 (9) (2008) 6491–6502.

[364] R. Hasan, L. Rink, H. Haase, Chelation of free Zn2+ impairs chemotaxis, phagocytosis, oxidative burst, degranulation, and cytokine production by neutrophil granulocytes, Biological trace element research 171 (1) (2016) 79–88.

[365] S. Yamasaki, K. Sakata-Sogawa, A. Hasegawa, T. Suzuki, K. Kabu, E. Sato, T. Kurosaki, S. Yamashita, M. Tokunaga, K. Nishida, Zinc is a novel intracellular second messenger, The Journal of cell biology 177 (4) (2007) 637–645.

[366] K. Nishida, R. Uchida, Role of zinc signaling in the regulation of mast cell-, basophil-, and T cell-mediated allergic responses, Journal of immunology research 2018 (2018).

[367] K. Nishida, A. Hasegawa, S. Nakae, K. Oboki, H. Saito, S. Yamasaki, T. Hirano, Zinc transporter Znt5/Slc30a5 is required for the mast cell–mediated delayed-type allergic reaction but not the immediate-type reaction, Journal of Experimental Medicine 206 (6) (2009) 1351–1364.

[368] H.J. Blewett, C.G. Taylor, Dietary zinc deficiency in rodents: effects on T-cell development, maturation and phenotypes, Nutrients 4 (6) (2012) 449–466.

[369] B. Bao, A.S. Prasad, F.W. Beck, G.W. Bao, T. Singh, S. Ali, F.H. Sarkar, Intracellular free zinc up-regulates IFN-γ and T-bet essential for Th1 differentiation in Con-A stimulated HUT-78 cells, Biochemical and biophysical research communications 407 (4) (2011) 703–707.

[370] S. Hojyo, T. Miyai, H. Fujishiro, M. Kawamura, T. Yasuda, A. Hijikata, B.-H. Bin, T. Irié, J. Tanaka, T. Atsumi, Zinc transporter SLC39A10/ZIP10 controls humoral immunity by modulating B-cell receptor signal strength, Proceedings of the National Academy of Sciences 111 (32) (2014) 11786–11791.

[371] T. Huang, G. Yan, M. Guan, Zinc Homeostasis in Bone: Zinc Transporters and Bone Diseases, Int J Mol Sci 21 (4) (2020).

[372] L. Rink, Zinc and the immune system, Proceedings of the Nutrition Society 59 (4) (2000) 541–552.

[373] R.S. MacDonald, The role of zinc in growth and cell proliferation, The Journal of nutrition 130 (5) (2000) 1500S–1508S.

[374] J. Eberle, S. Schmidmayer, R. Erben, M. Stangassinger, H. Roth, Skeletal effects of zinc deficiency in growing rats, Journal of trace elements in medicine and biology 13 (1-2) (1999) 21–26.

[375] J. Yu, L. Xu, K. Li, N. Xie, Y. Xi, Y. Wang, X. Zheng, X. Chen, M. Wang, X. Ye, Zinc-modified calcium silicate coatings promote osteogenic differentiation through TGF-β/Smad pathway and osseointegration in osteopenic rabbits, Scientific reports 7 (1) (2017) 1–13.

[376] J. Chou, M. Komuro, J. Hao, S. Kuroda, Y. Hattori, B. Ben-Nissan, B. Milthorpe, M. Otsuka, Bioresorbable zinc hydroxyapatite guided bone regeneration membrane for bone regeneration, Clinical oral implants research 27 (3) (2016) 354–360.

[377] Y. Song, H. Wu, Y. Gao, J. Li, K. Lin, B. Liu, X. Lei, P. Cheng, S. Zhang, Y. Wang, J. Sun, L. Bi, G. Pei, Zinc Silicate/Nano-Hydroxyapatite/Collagen Scaffolds Promote Angiogenesis and Bone Regeneration via the p38 MAPK Pathway in Activated Monocytes, ACS Appl Mater Interfaces 12 (14) (2020) 16058–16075.

[378] T. Kambe, T. Tsuji, A. Hashimoto, N. Itsumura, The Physiological, Biochemical, and Molecular Roles of Zinc Transporters in Zinc Homeostasis and Metabolism, Physiol Rev 95 (3) (2015) 749–784.